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SYNOPSIS
Following the confirmation of DNA as the genetic material in the 1950’s,
work focussed on how this information is translated into the functional
components from which cells are composed.  The controlled transcription of
specific coding regions into RNA lead to the discovery of a variety of RNA
polymerases, which were later shown to differ based on the purpose of the
RNA which they produce.  Eucaryotic cells possess three distinct RNA
polymerases for production of the three major catagories of cellular RNA: Pol I
(28 S-, 18 S- and 5.8 S-ribosomal RNA); Pol II (messenger RNA); Pol III (5 S-
ribosomal RNA; transfer RNA).  However, only Pol II transcripts (mRNA) are
further translated into proteins.
The results of the human genome project suggest the presence of
approximately 30,000 genes, whose coding regions occupy less than 5 % of the 6
x 109 DNA base pairs from which it consists.  Not all genes are expressed:  the
pattern of gene expression differs between cell types, and changes in response
to cellular signals.  The mechanism by which this is controlled requires the
presence of gene-proximal sequences (promoters and enhancers), and proteins
that specifically bind to them (transcription factors) in order to recruit the RNA
polymerase.
Unlike the other RNA polymerases, RNA Pol II is extensively modified by
a variety of enzymes that can influence its initiation, elongation and the
processing of pre-mRNAs, in a promoter specific manner.  Although the
enzymatic core of all three mammalian RNA polymerases is almost identical,
large differences are seen with their external surfaces, no more apparent than
that of the C-terminal domain (CTD) of the RNA polymerase II large subunit:  a
378 amino acid structure that is absent in all other polymerases.
 The CTD of RNA polymerase II consists of 52 repeats of a heptapeptide
consensus sequence, tyrosine - serine - proline – threonine – serine – proline -
serine (YSPTSPS), an unusual sequence in that it contains a high percentage of
phosphorylation sites (Payne and Dahmus, 1993).  Nearly 20 years after its
identification, the exact role of CTD still remains enigmatic:  CTD is required for
transcription initiation, RNA elongation, and the recruitment of important
factors for mRNA capping, splicing, and 3‘-processing.  Exactly how CTD fulfils
these functions has been complicated by conflicting in vitro and in vivo data:  the
CTD appears unimportant for in vitro transcription.  This observation, and an
increased understanding of the role of chromatin in transcription regulation
made the development of good in vivo systems a necessity.  The development of
a tetracycline-inducible, α−amanatin-resistant RNA polymerase II expression
system by this laboratory was such a development:  for the first time, an
exogenously expressed mutant RNA polymerase II large subunit could be
tested in vivo, on the endogenous, chromatin template.  This system was
initially used to study the importance of CTD length, based on the differences
seen between different organisms.  During this time, a plethora of research
appeared regarding the specific phosphorylation of the CTD by various kinases,
and the factors recruited as a result.  Chromatin immunoprecipitation
experiments by the Buratowski laboratory imply position-specific changes in
phosphorylation, resulting in the sequential recruitment of factors for pre-
mRNA processing during the transition from early to late elongation phases.
The kinases (CDKs 7, 8 and 9) involved in these processes are probably
involved in the transcription of every gene.  Despite expressing some
preference for consensus or non-consensus CTD repeats in vitro, the patterns of
phosphorylation produced in vivo and what factors they specifically recruit
remains speculation.
The discovery that other enzymes act on the CTD in a non-general,
stimulus-specific way is cause for much interest.  What signal is conveyed to
the transcription machinery and for what purpose?  Through this work I have
tried to elucidate the purpose of the last CTD repeat of the RNA Pol II large
subunit, a sequence known to be the target of the kinases CKII, c-Abl and c-Arg.
At present, this is the only known specific site of interaction for CTD kinases.
Contrary to earlier speculation, no effect on transcriptional elongation could be
seen when this domain was removed, suggesting that these interactions serve
some other function.  The removal of the last repeat had no effect on the
induction of specific gene transcription in response to ionising radiation,
indicating that the phosphorylation of the CTD by c-Abl is not important for
this function.  Analysis of CKII site point mutants confirmed previous
suggestions that the greater number of acidic amino acids surrounding serine
13 of the last repeat make it the preferential site for CKII phosphorylation.
Mutation of the CKII phosphorylation sites within this domain had no notable
effect on any aspects of function tested, indicating that this modification may be
redundant, or of little importance.  However, complete removal of this domain,
or severe mutation thereof, resulted in the proteolytic degradation of the large
subunit to the CTD-less, Pol IIb form – a form previously only seen in vitro.
This form is probably inactive in vivo, suggesting that the last CTD repeat might
be involved in a mechanism by which the activity of RNA polymerase II is
regulated through its specific degradation.
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1. Introduction
1.0 Overview
The tight regulation of gene expression is essential to all cellular
organisms in order to respond to changing environments, and for the
regulation of their growth, development, proliferation, and even death in more
complex organisms.  Gene expression starts with the copying of coding
deoxyribonucleic acid (DNA) sequences into a ribonucleic acid (RNA)
transcript (Transcription), which itself is then used as the template for protein
synthesis (Translation).  The DNA dependent RNA-polymerases, responsible
for transcription of RNA, are composed of multiple protein subunits that
assemble to form a so-called ‘transcription complex’.  The components of these
complexes provide not only the enzymatic function for RNA synthesis, but
regulate the ability of the enzyme to initiate, elongate and terminate
transcription of a template.
A major difference between the genomes of higher organisms to that of
procaryotes is the packaging of DNA in to chromatin.  Not only does chromatin
serve to structurally organise the DNA in the nucleus, but also functions as a
general mechanism of gene repression.  Only when this repression is removed
can transcription occur.  Transcription by all polymerases is thus dependent on
the presence of accessory factors that may activate or repress gene expression
through the modulation of chromatin structure.
1.1 The regulation of gene expression through chromatin
Eucaryotic transcriptional control can be divided into two modes of
regulation:  at the level of chromatin and through the recruitment and
activation of RNA polymerase II.  Although similarities to procaryotes exist, the
large size of eucaryotic genomes requires its packaging in order to prevent it
occupying many times the cell volume.  Since not all genes are required for
every cell type, only those required are in an accessible form of chromatin.  This
in turn requires a more complex transcription apparatus to transcribe through
it.
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The nuclear DNA is complexed with histone and non-histone proteins.
The DNA double helix is stored in beads, called nucleosomes, which consist of
two molecules each of the histone proteins H2A, H2B, H3 and H4.
Nucleosomes form on approximately every 200 base pairs of DNA, with 146
base pairs wrapped around each nucleosome, and the rest forming a linker to
the next.  This first packaging step already reduces the DNA molecule to one-
third of its original size.  Histone H1 forms contacts with both nucleosomes and
DNA, optimising the exit path of DNA from a nucleosome to improve stacking,
and thereby producing a 30 nm nucleosome fibre.  This type of packaging
accounts for the majority of DNA in a typical mammalian cell (euchromatin),
with about one tenth being in a more highly packaged, inaccessible form
(heterochromatin).
 The binding of nucleosomes to DNA is not sequence specific, but due to
steric constraints, expresses a preference for A-T rich regions, leading to
irregular spacing.  More importantly, nucleosome positioning is also regulated
by the binding of proteins to DNA regions.  This results in the exact positioning
of nucleosomes along certain stretches of DNA, and influences the access of
other proteins to these regions.  The promoter regions of most genes have a
defined nuclear structure, that is modulated to influence the recruitment and
initiation of transcription complexes.
1.1.1 Chromatin remodelling
In order for transcription factors and RNA polymerase II to bind to
promoters, the nucleosome structure must first be altered to permit access.
Specialised proteins can bind this packaged DNA, and using the energy of ATP
hydrolysis, may change the structure of nucleosomes temporarily to allow their
movement.   The remodelled state probably results from movement of the H2A-
H2B dimers in the nucleosome core (Kireeva et al., 2002), since the H3-H4
tetramer is very stable and therefore difficult to rearrange.  Two families of
multiprotein remodelling complexes have so far been identified:  SWI/SNF and
ISWI (imitation switch).  They distinguish themselves from one another
through their helicase/ATPase components:  SWI/SNF family members
perturb the nucleosome core-particle structure, whereas ISWI complexes
function to shift nucleosomes to different locations on the DNA.   Nevertheless,
both complexes contain common subunits, but how their specificity and activity
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is regulated is still not known.  Incubation of nucleosome-bound DNA with
these complexes creates ‘nuclease-hypersensitive sites’ due to the formation of
nucleosome-free regions.  Such sites have been found to contain the enhancers
and promoters of transcriptionally active genes, exposure of which is an
important step early in transcription activation, explaining why the SWI/SNF
complex is one of the first co-activators to be recruited to a locus initiating
transcription (Cosma et al., 1999).  Importantly, remodelling complexes may
also function to repress transcription through the formation of inaccessible
chromatin structures.
1.1.2 Modification of histone tails alters the properties of nucleosomes
The study of transcriptional activators has revealed one of their major
functions to be the recruitment of enzyme ‘co-activators’, that often contain
catalytic activities towards histones.  Histone tails are subject to several
modifications that influence the ability of their containing nucleosomes to form
stable higher chromatin structures, for example, the 30 nm chromatin fibre.
Acetylation of the positively charged lysine residues in histone tails by histone
acetyl-transferase (HAT) activities may influence the ability of histones to
neutralise the charges on DNA, thereby reducing the stability of such higher
structures.  The recruitment to promoter regions of HAT-containing co-
activators, such as p300 and CBP (cAMP-responsive-element-binding (CREB)-
binding protein), opens nucleosome-bound templates to allow the access of
other remodelling factors.  Histone tails are subject to other modifications, for
example, methylation and ubiquitinylation.  Such modifications may function
to specifically recruit regulatory and structural proteins to modulate the
compaction of chromatin.  In telomeric DNA, under acetylation of histone H4
tails has been shown to recruit complexes of Sir proteins (Sir2 is itself a histone
deacetylase) to assist the condensation required for the formation of
heterochromatin.
 The architecture of promoters is therefore governed by an interplay of
positive (HATs) and negative (HDACs; methylases) factors, which in turn
influence the accessibility of the general transcription machinery, and thus the
initiation of transcription.
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1.2 RNA polymerase II
The eucaryotic RNA polymerase II consists of a 12 subunit, > 0.5MD
complex with two magnesium ions in its active site (Cramer et al., 2001). The
two largest subunits, RPB1 (approx. 220 kDa) and RBP2 (approx. 140 kDa), form
the catalytic domain through which the DNA-RNA assembly from
ribonucleotides takes place.  These two subunits exhibit structural and
functional homology to the ß and ß’ subunits of the E. coli RNA polymerase.
The elucidation of the crystal structure of RNA polymerase II (Cramer et al.,
2000; Cramer et al., 2001) has revealed that the enzymatic core structure of
bacterial and mammalian polymerases is highly conserved through evolution.
Sequence comparison of RPB1 and RPB2 to  ß and ß’ revealed homology in 8 of
9 core domains within their structure.  The linking regions between these
domains may have evolved to allow enhanced functions of the polymerase
complex.  Conservation is also seen between the three eucaryotic polymerases:
Pol II contains five subunits that are also present in Pols I and III (Bushnell et
al., 2002).
The large subunit of RNA polymerase II (RBP1) differs strikingly from
other eucaryotic polymerases in its possession of a unique C-terminal domain
(CTD).  The CTD of eucaryotic RBP1 consists of repeats of the consensus hepta-
peptide sequence YSPTSPS (Corden et al., 1985).  The consensus sequence is
highly conserved across organisms, but the number of repeats appears to have
increased through evolution (Fig. 1.) (Stiller and Hall, 2002); the more complex
an organism, the greater the number of repeats:  Plasmodium has 17,
Saccharomyces 26 or 27, Drosophila ≈45, and mice and humans 52 repeats (Allison
et al., 1988).
 Deletions of more than half of the repeats in the yeast, or mouse CTD
interferes with cell viability.  Mice homozygous for a deletion of 13 repeats are
smaller then wild type littermates and have a high rate of neonatal lethality,
suggesting that the CTD is important in growth regulation during mammalian
development (Litingtung et al., 1999).  Tissue culture experiments to test the
importance of CTD length in mammalian cells have demonstrated that a
truncation to 31 repeats, although capable of transcription of hsp70A and c-fos
genes (Meininghaus et al., 2000; Meininghaus and Eick, 1999), is growth
limiting and cannot replace the endogenous RPB1 with respect to long-term
survival.   A truncation to five repeats exhibits a global defect in transcription
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on a native template, and is thus unable to support life (Meininghaus et al.,
2000).
The CTD becomes heavily phosphorylated at a specific phase of the
transcription cycle (Cadena and Dahmus, 1987; Dahmus, 1994), the number of
phosphorylation sites exceeding 50 (Payne and Dahmus, 1993).  The
phosphorylation status of the CTD has been shown to be essential for
regulation of gene expression.  Only the non-phosphorylated (IIA) form of Pol
II can participate in the formation of a pre-initiation complex (PIC), while CTD
phosphorylation is essential for transcriptional elongation (the IIO form)
(Cadena and Dahmus, 1987; Payne et al., 1989).  Stress induced phosphorylation
of non-DNA-bound Pol II by kinases, such as ERK, may function to down
regulate transcription by preventing the formation of new PICs (Bonnet et al.,
1999; Dubois et al., 1994).  Recently, it has been shown that phosphorylation of
serines 2 and 5  (YS2PTS5PS) differs dependent upon the position of the
RNAPII complex (Komarnitsky et al., 2000).  A bias toward serine-5
phosphorylation is observed in the CTD of polymerases in promoter regions,
while more serine-2 phosphorylation is observed during transcription of coding
regions.  Such phosphorylation events create specific phospho-amino acid
motifs allowing selective recruitment of accessory proteins to the CTD in a
kinase dependent manner.  The CTD of the elongating form of Pol II in vivo
contains an estimated 50 phosphorylated amino acids, of which the majority
being serine (Hengartner et al., 1998).  The phospho-CTD binding partners so
far described exhibit dependence for phospho-serine; roles for phospho-
threonine and phospho-tyrosine are yet to be described.  The structure of the
CTD may be further modified through isomerisation of proline residues from
cis- to trans- conformations by the parvulin family isomerase Pin1 (Albert et al.,
1999), and cyclophilin SRcyp/CASP10.  These proteins have been implicated in
controlling access to the phospho-CTD, of co-factors involved in 3’ pre-mRNA-
end formation, and the ubiquitination of RPB1 (Carty et al., 2000; Chang et al.,
2000; Cho et al., 1997; Goldstrohm et al., 2001; Lindstrom and Hartzog, 2001;
Morris and Greenleaf, 2000; Morris et al., 1999).  The hypophosphorylated form
of RPB1 (Pol IIa) has also been found to undergo glycosylation, through the
addition of O-linked N-acetyl glucosamine residues (O-GlcNac) to the CTD, the
purpose of which is not known (Kelly et al., 1993)
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Figure 2. The amino acid sequence of the final non-consensus repeat of the RNA
polymerase II (RPB1) subunit.  In some organisms, an unusual domain is
found at the C-terminal end of the CTD, in mammals refered to as the 52nd,
or ´last´ CTD repeat.  Residues conforming to the CTD consensus sequence
(YSPTSPS) are labelled black; acidic residues, green; basic residues, blue;
neutral residues, red.
1.3 The last repeat of the RNA polymerase II CTD
The repeat sequence of the CTD increasingly deviates from the consensus
sequence (YSPTSPS) with proximity to the carboxy-terminus.  The evolution of
longer CTDs, and non-consensus repeats have been speculated to attribute
specific functions to different regions of the CTD (Fong and Bentley, 2001).  A
comparison of different organisms reveals the development of divergent C-
terminal sequences of unknown purpose, often referred to as the last repeat
(Fig. 2).  These sequences not only differ in their amino acid composition, but
also length:  the last repeat of Plasmodium falciparum CTD consists of 68 amino
acids; Caenorhabditis elegans, 5 amino acids; and Saccharomyces pombe ends in a
simple consensus repeat.  Despite the great diversity seen between species, it is
interesting to note the presence of similar acidic amino acids in the last repeat of
both Drosophila melanogaster and mammalian CTDs.
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Figure 3. Signalling to the last 17 amino acids of the mammalian RNA
polymerase II CTD. (A) A simplified model of potential kinase activities at
an E2F-1 regulated promoter.  Active Rb binds and inhibits both E2F-1 and
c-Abl.  Following deactivation of Rb by CDK4/6 at the G1/S phase
transition, E2F-1 may stimulate initiation and elongation of RNA
polymerase II.  The initiation-associated kinase of the TFIIH general
transcription factor (CDK7/ cyclin H), and the kinase of the elongation
factor P-TEFb (CDK9/ cyclin T), may differentially phosphorylate serines
at positions 2 and 5 in each repeat of the CTD.  (B) The ATM kinase
activates c-Abl and p53 in response to a specific type of DNA damage
caused by ionising radiation (IR). The c-Abl tyrosine kinase, recruited to the
promoter by Rb can bind and phosphorylate tyrosines in the CTD, but only
following activation by ATM (*).  c-Abl recognises a motif lying within the
52nd repeat that it requires for binding to, and efficient phosphorylation of
the CTD.  The CTD contains three consensus phosphorylation sites for the
casein kinase II (CKII): one contained in repeat 37; two in the final 17
amino acids of CTD which constitute repeat 52.
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Between mammals, the sequence is 100% conserved, suggesting it may have
evolved to serve an important new function in higher organisms.  Indeed, the
mammalian final repeat contains a total of 17 amino acids, forming what
constitutes two potential casein kinase II (CK II) recognition sites (Bregman et
al., 2000), and is essential for recognition by the tyrosine kinases c-Abl and c-
Arg (Baskaran et al., 1997a; Baskaran et al., 1999).  The purpose of these
interactions is not known, but a consideration of current knowledge of the CTD,
and its phosphorylation by specific kinases may assist our understanding.  It is
possible that individual promoters may be regulated by specific CTD kinases.
Figure 3 depicts a simplified view of the kinases present at an E2F-1 regulated
promoter:  in addition to transcription-associated cyclin-dependent kinases, the
presence of E2F-1 indirectly recruits c-Abl through its interaction with Rb.
1.4 Initiation of transcription
Changes in the chromatin structure of certain control regions influences
the access of activator proteins to stimulate the recruitment of a pre-initiation
complex to a gene promoter region.  These elements may be located many
kilobases away, and may assert a positive ('enhancer'), or negative ('silencer')
influence on transcription of a gene locus (Seipel et al., 1992).
Unlike procaryote RNA polymerase, mammalian RNA polymerase II is by
itself unable to initiate and complete the transcription of a gene.  Additional
proteins, called the general transcription factors (GTFs), are first required to
bind a promoter before the recruitment of Pol II.  These proteins are ‚general’
because they are required by all promoters used by Pol II.  The text book model
of PIC assembly starts with promoter binding of TFIID, followed by TFIIA,
TFIIB, TFIIE, TFIIH and the remaining GTFs, including Pol II.  Not surprisingly,
the promoters of class II eucaryotic genes contain elements to direct the binding
of GTFs.  The transcription start site usually contains a pyrimidine-rich initiator
element (INR), with the consensus sequence  (Py)2A+1
A/T(Py)2, that binds the
GTF, TFIID.  Approximately 25-30 bp upstream from INR lies the TATA box
(Consensus sequence TATA A/T A 
A/T), an element recognised and bound by the
TBP (TATA-binding protein) subunit of TFIID.  Binding of TFIID to the TATA
box causes an ≈80° kink in the promoter DNA thereby enabling the binding of
TFIIB to the adjacent BRE element (Consensus: G/C 
G/C
 G/A CGCC), which lies 35
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bp upstream from INR.  Binding of TFIIB stabilises the binding of TFIID to
DNA, forming the interface for recruitment of the Pol II/TFIIF complex.  Unlike
most other transcription factors TFIID also binds a sequence in the transcribed
region downstream of INR:  the DPE element (Consensus: A/GG
A/T CGTG).
TFIID is composed of at least eight TBP-associated factors (TAFs) which
probably function in the specific recognition of promoters, and activator-
stimulated transcription (Komarnitsky et al., 1999).  Interestingly, a TAF-
containing complex (TFTC) produced by depleting TBP from TFIID, still
permits basal and activated transcription of TATA-containing and TATA-less
promoters.  Several TAFs exhibit sequence and structural homology to histones
and their properties of DNA binding may, alike the bacterial sigma factor, assist
recognition of specific promoter sequences.  As mentioned, only non-
phosphorylated Pol II (Pol IIA) can form initiation complexes.
Dephosphorylation is probably achieved through a CTD-specific phosphatase
FCP1, which associates with, and is stimulated by TFIIF.
PIC formation results in the ATP-dependent melting of DNA in the region
of  the transcription start site.  The  mammalian TFIIH complex consists of nine
subunits and is the only GTF possessing ATP-dependent enzymatic activities
(Dvir et al., 1996).  TFIIH contains two helicases encoded by the Xeroderma
pigmentosum complementation group B (XPB) and D (XPD) genes, and the CTD-
and cyclin-dependent kinase cdk7/cyclin H (Moreland et al., 1999).  Initiation is
completed following the completion of the first phosphodiester bonds of the
RNA transcript (Kugel and Goodrich, 2002).
Since this model of assembly  was based on in vitro data, the exact order in
which GTFs actually assemble on promoters in vivo is not certain.  However,
studies in yeast suggest that the GTFs and Pol II exist in a pre-assembled form
called a 'holoenzyme', containing TFIIB, TFIIF, TFIIH and the SRB (Suppressor
of RNA polymerase B)/Mediator protein (Koleske and Young, 1995).  The
holoenzyme model suggests initiation is not regulated through the assembly of
the individual PIC components, rather the rate with which the activators recruit
a holoenzyme to a promoter.  Transcriptional activator proteins bind to TFIIB,
TFIID and TFIIH, and genetic evidence implicates these interactions in gene
activation in vivo.  However, transcriptional activators fail to stimulate
transcription reconstituted with Pol II and the GTFs in vitro.  The reaction
requires the addition of a protein complex called 'Mediator', which provides the
interface between activator and holoenzyme (Mittler et al., 2001).  Mediator is
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thought to integrate and transduce positive and negative regulatory
information from enhancers and operators to promoters (Kornberg, 2001).
1.4.1 The Mediator complex
Mediator was originally isolated as a 20-subunit complex from yeast, and
corresponding complexes have since been found in mice and human cells.
Two-thirds of the Mediator subunits are products of genes previously identified
in screens in yeast for mutations that affect transcription control, demonstrating
the importance of Mediator for in vivo regulation (Myers et al., 1999; Myers and
Kornberg, 2000).  The Mediator subunits can be divided in to three groups:  the
products of the five SRB genes, characterised as interacting with the RPB1 CTD;
the products of four genes identified as global suppressors, and six members of
a new protein family, termed Med, implicated in transcriptional activation.
Mediator is only associated with initiation complexes (Pokholok et al., 2002).
Reconstitution experiments in vitro have shown mediator to stimulate the
phosphorylation of CTD by  the TFIIH kinase 30- to 50-fold.  Since Mediator
binds only hypophosphorylated CTD, this function may serve to release itself
from the initiation complex once the signal for elongation is received.  This is
supported by evidence for the recycling of Mediator to initiation complexes and
the absence of Mediator from elongating polymerases (Pokholok et al., 2002;
Svejstrup et al., 1997).  The transition to elongation was subsequently shown to
involve the replacement of Mediator with an elongation complex termed
'Elongator' (Otero et al., 1999).
1.5 Transcription elongation
The exact mechanisms of transition from the initiation phase to the
elongation phase are confused by conflicting data from in vitro and in vivo
systems.  However, the process can be broken down in to five defined steps:
PIC formation, initiation, escape commitment, promoter escape, and transcript
elongation.  It is proposed that following synthesis of a 4-nt RNA, a
conformational change occurs in the ternary transcription complex, rendering it
insensitive to otherwise inhibitory single stranded RNAs, and thus escape
committed (Kugel and Goodrich, 2002).  Promoter escape is accomplished after
1.  Introduction 12
the synthesis of a 10-15-nucleotide-long transcript, leading to the release of Pol
II from initiation factors and the promoter (Conaway et al., 2000).  Early Pol II
elongation complexes containing transcripts of less than approximately nine
nucleotides in length are unstable, and are prone to abortive transcription
(Fiedler and Timmers, 2001).
 Elongation complexes lack basal factors, with the exception of TFIIF,
which in addition to being required for initiation (Dvir et al., 2001) is also an
elongation factor, and acts during the early stages of elongation to decrease the
frequency of abortive transcription.  It has been proposed that TFIIF functions
to stabilise the tight interaction of the PIC with promoter DNA and facilitates its
unwinding during the formation of the open complex (Yan et al., 1999).
1.5.1 General elongation factors
A variety of positive and negative elongation factors exist, which may
direct the elongation, arrest, or abortion of transcription complexes.  The
tendency of early Pol II elongation complexes in vitro to arrest can be overcome
by the GTFs, TFIIE and TFIIF, in a reaction that requires the ATP-dependent
XPB DNA helicase activity of TFIIH (Dvir et al., 2001; Moreland et al., 1999).
Unlike a classical DNA helicase, XPB induces opening by twisting promoter
DNA (Fiedler and Timmers, 2001).  This may function to assist the release of
TFIIF-DNA contacts, that although essential for initiation, may impede
elongation (Conaway et al., 2000).
It is suggested that RNA polymerase traverses a DNA template either by
I) the continuous addition of nucleotides, one after the other (monotonous), or
more probable, II) in a discontinuous manner, through phases of expansion and
contraction ('inchworming') (Chamberlin, 1992; Nudler et al., 1994). Structural
comparisons of bacterial and eucaryotic RNA polymerases has allowed
speculation as to the paths taken by the DNA, NTPs and RNA product within
the complex.  A highly conserved structure, the 'bridge helix', traverses the
active site of both polymerases, but is straight in Pol II and bent in the bacterial
structure.  The bridge helix forms contacts with the end of the DNA-RNA
hybrid in elongation complexes, and is speculated to provide elasticity to the
translocating complex, while firmly maintaining nucleic acid-protein
interaction (Cramer et al., 2001).   Addition of a nucleotide to the growing RNA
strand provides energy for the distortion of the complex, which is only reversed
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upon forward translocation to the next position, or through a reverse
translocation at pause- or termination-sites.  Elongation blocks imposed by
inhibitory structures, or proteins bound to the template cause transient stalling
of elongation complexes, which in some cases may convert to stable
transcriptional arrest.  Arrest leads to backtracking of the polymerase and
removal of the 3’-end of the nascent RNA from the active site, through the NTP
access pore of the 'cleft' domain (pore1) in to the funnel (Cramer et al., 2001),
where it is subject to degradation by Pol II’s proof-reading endonuclease
activity.  The transcription elongation factor TFIIS/SII has been shown to
reactivate such complexes by stimulating exonucleolytic cleavage of the nascent
RNA, thereby realigning the 3’-end in register with the catalytic centre
(Reviewed in:  Pal and Luse, 2002; Sijbrandi et al., 2002; Wind and Reines, 2000).
TFIIS probably binds via funnel in the proximity of pore1, and may induce
allosteric changes in the catalytic centre, to stimulate Pol IIs exonucleolytic
activity upon DNA:RNA mismatch, or backtracking of arrested complexes
(Powell et al., 1996; Sijbrandi et al., 2002).
1.5.2 The Elongator complex
Elongating RNA polymerase II is  associated with the multi-subunit
complex Elongator, whose stable interaction is dependent on
hyperphosphorylation of the Pol II CTD (Otero et al., 1999).  Elongator was
identified in yeast as consisting of the products of the genes ELP1-ELP6
(Fellows et al., 2000; Winkler et al., 2001).  Purified Elongator can exist in two
forms:  an unstable, six-subunit complex, the so-called 'holo-Elongator', which
possesses HAT activity directed against histones H3 and H4 (Winkler et al.,
2002), and a three-subunit core form consisting of Elp1-3, which lacks HAT
activity, despite the presence of the Elp3 HAT (Hawkes et al., 2002).  This
anomaly was recently elucidated by the finding that the three smallest
Elongator subunits - Elp4, Elp5 and Elp6 – are required for the HAT activity of
Elp3 (Winkler et al., 2002).  Deletion of ELP genes in yeast cells results in a
variety of phenotypes consistent with a role for the factor in transcription
elongation.  Importantly, mutations that destroy the HAT activity of Elp3 in
vitro, also produce elp phenotypes in vivo, suggesting that the HAT activity of
Elongator is essential for its function (Winkler et al., 2001; Wittschieben et al.,
2000).  Deletion of ELP3 is synthetically lethal with deletion of the tail of histone
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H4, or of the Rpb9 subunit of RNA polymerase II and confers a severe growth
defect with the gene encoding the Gcn5 subunit of the SAGA complex (Van
Mullem et al., 2002; Winkler et al., 2002). It is to be noted however, that despite
the growing evidence for Elongator function, recent work in yeast has been
unable to detect Elongator associated with Pol II under any conditions, and
revealed that the majority of Elongator is cytoplasmic (Pokholok et al., 2002).
1.6 Control of elongation
The transition to elongation has been shown to involve an interplay of
positive and negative elongation factors.  A wealth of data suggests that this
transition in vivo is dependent on the phosphorylation of the Pol II CTD.  The
phosphorylation status of CTD is dynamic throughout the transcription cycle:
the phosphorylation patterns created by CTD kinases function to specifically
recruit and displace factors for elongation and pre-mRNA processing at
different stages of transcription (Komarnitsky et al., 2000).
1.6.1 Cyclin-dependent kinases regulate in vivo transcription
The specific pattern of phosphorylation of serines-2 and -5 (YSPTSPS) of
each repeat has been shown to change with the transition from initiation to
elongation (Komarnitsky et al., 2000).  A plethora of recent publications has
identified many factors that associate with specific phosphorylated or non-
phosphorylated forms of CTD, but the regulation of this differential
phosphorylation, and the kinases responsible is not clear.  The CTD kinases of
the initiation-associated general transcription factor TFIIH (CDK7/cyclin H),
and elongation factor P-TEFb (CDK9/cyclins T1, T2 and K) have been shown in
vitro to preferentially phosphorylate serine-5, but this does not discount the
possibility that when augmented by other factors, these kinases may be directed
towards serine-2 in vivo (Reviewed in Oelgeschlager, 2002).  Indeed, the
putative homologue of P-TEFb, the CtkI subunit of the S. cerevisiae CTD kinase
CTDK-I, specifically directs its kinase activity towards serine-2 (Cho et al.,
2001).
The ability of these transcription-associated CTD kinases to dynamically
regulate the interactions of Pol II with elongation and processing factors has
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brought to question the purpose of other CTD-modifying enzymes that act only
under certain conditions.
1.6.2 The inhibition of transcription through CTD phosphorylation
Since only hypophosphorylated Pol II CTD (IIA) may stably initiate at
promoters, CTD phosphorylation prior to this event prevents initiation.  The
CDK8/cyclin C subunits of the Mediator complex (SRB10/SRB11 in yeast) may
inhibit transcription through the phosphorylation of cyclin H of the
CAK/TFIIH complex. CDK8/cyclin C also phosphorylates CTD, with
preference for consensus repeats.  The cyclin-dependent kinase, p34CDC2, that
triggers entry into mitosis also stimulates the pre-initiation
hyperphosphorylation of Pol II CTD, TFIID and CDK7 to inhibit transcription
(Reviewed in Bregman et al., 2000).
The p42, p44 ERK 1/2 kinases have also been shown to directly
phosphorylate the CTD, resulting in the accumulation of a novel form of RPB1,
called IIm, that migrates at a speed between IIo and IIa (Bonnet et al., 1999).  In
vitro studies suggest ERK 1/2 targets serine-5 of the CTD repeats, with no
apparent preference for consensus or non-consensus repeats (Trigon et al.,
1998).  ERK 1/2 phosphorylation of CTD is induced in response to stressful
stimuli such as heat or osmotic shock, oxidative stress and ionising radiation
(Bonnet et al., 1999).  Additionally, ERK 1/2 activity prior to fertilisation
inhibits transcription, and possibly leads to sequestration of the
hyperphosphorylated (IIM) Pol II form (Reviewed in Oelgeschlager, 2002).  It is
not known whether these modifications may also function to target specific
factors to the polymerase complex.
1.6.3 CTD phosphorylation displaces negative elongation factors
The hypophosphorylated Pol II associates with the negative elongation
factors DSIF (DRB sensitivity inducing factor) and NELF (Negative elongation
factor) (Yamaguchi et al., 1999).  The positive Pol II elongation factor P-TEFb,
composed of CDK9 and one of its cyclins (cyclin T1, T2a, T2b or K) (Peng et al.,
1998), acts following promoter clearance to phosphorylate itself, the Pol II CTD,
TFIIF and the SPT5 subunit of DSIF (Majello and Napolitano, 2001).  Activation
of P-TEFb counteracts the inhibition by DSIF (Wada et al., 1998) and NELF to
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stimulate elongation (Reviewed in Oelgeschlager, 2002).  Transcriptional
elongation is blocked by potent inhibitors of P-TEFb such as 5,6 dichloro-1-β-D-
ribofuranosylbenzimidazole (DRB) and Flavopiridol suggesting it to be a major
elongation kinase (Barboric et al., 2001).   This is supported by the finding that
many transcription factors such as NFkB (Barboric et al., 2001), CIITA
(Kanazawa et al., 2000), and HIV Tat (Wei et al., 1998) function to recruit P-
TEFb to promoters and thereby stimulate transcription elongation.
1.7 CTD modifying enzymes of unknown function
A variety of enzymes have been identified that can modulate the structure
of the CTD, however, the purpose of such modifications is not yet clear.  The
response to DNA damage resulting from a double-stranded break activates the
DNA-dependent protein kinase (DNA-PK) family members Ataxia-
telangiectasia-mutated (ATM) and DNA-PK.  The DNA-PK, but not ATM has
been shown to directly phosphorylate CTD (Peterson et al., 1995).  ATM
activates the c-Abl tyrosine kinase, which via a specific domain, the CTD-ID,
binds to, and phosphorylates the CTD (Fig. 2B) (Baskaran et al., 1996).  It has
been speculated that these activities function to modulate the expression of
specific genes in response to DNA damage and in HIV transcription elongation
(Baskaran et al., 1993; Baskaran et al., 1999).
Another cyclin-dependent kinase, PITSLRE (now called CDK11) and
cyclin L, have been shown to bind the hyperphosphorylated form of the CTD,
as well as to the Elongator subunit ELL2.  CDK11 was co-purified with
hyperphosphorylated CTD and another CTD kinase activity that was shown to
be casein kinase II (CKII).  However, this interaction has led to CDK11/cyclin L
being incorrectly identified as a CTD kinase (Kidd V.J., personal
communication).
The Pin1 peptidyl-prolyl, cis-trans isomerase (PPIase) has been shown to
bind hyperphosphorylated CTD and may alter its conformation (Morris et al.,
1999).  Recent results suggest this isomerisation is important for the efficient
dephosphorylation of the CTD by the FCP1 phosphatase (Kops et al., 2002).
Pin1 is thought to play a role in mitosis control, through the binding and
isomerisation of cell cycle regulatory proteins but has more recently been linked
to chromatin remodelling complexes and the general transcription machinery
(Wu et al., 2000).  Interestingly, Pin1 also interacts with the CK2α subunit of
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CKII and inhibits its ability to phosphorylate topoisomerase IIa (Messenger et
al., 2002).
1.7.1 CKII phosphorylation of the CTD
Despite its early discovery, the precise role of CKII still remains elusive
(Allende and Allende, 1995).  Nuclear CKII activity is required for cell cycle
progression in the G1 phase of cell cycle, and is implicated in the responses to
genotoxic and other stresses.  CKII interacts with, and phosphorylates many
factors associated with the regulation of growth and apoptosis:  p53 (Keller et
al., 2001); the p65 subunit of NF-κB (Wang et al., 2000), and its inhibitor IκB
(McElhinny et al., 1996); the caspase 8-inhibiting protein ARC (Li et al., 2002); c-
Myc induces growth, but apoptosis in the absence of growth factors (Luscher et
al., 1989).
The consensus sequence for CKII phosphorylation is (S/T)XX(D/E)
(Pinna, 1990) and is found once in the non-consensus repeat 37 and twice in the
final repeat of the Pol II CTD (Fig. 2B).  It has been shown that CKII
phosphorylates CTD (Dahmus, 1981), but not a fragment containing just
consensus repeats (Bregman et al., 2000). Stoichiometric analysis suggests only
one of these sites becomes phosphorylated in vivo, likely the most C-terminal
serine (position 1966; serine 13) of the last CTD repeat, given the preference of
CKII for sites surrounded by acidic residues (Kuenzel et al., 1987; Payne et al.,
1989).  Results from one study suggest the final repeat to be continuously in the
phosphorylated state (Palancade B. & Bensaude O. personal communication),
and that this phosphorylation is not necessarily CKII dependent, given that
only Pol IIa, and not Pol IIo is a CKII substrate (Cadena and Dahmus, 1987;
Payne et al., 1989).
1.7.2 Phosphorylation of tyrosine in the CTD
Some CTD tyrosine phosphorylation can be detected in cell lines lacking c-
Abl, suggesting the presence of other CTD-tyrosine kinases (Baskaran et al.,
1993).  Indeed, the product of the Abl-related gene, c-Arg also contains a CTD-
ID domain, and can also phosphorylate the Pol II CTD.  However, unlike c-Abl
it is not known what signal induces phosphorylation of CTD by c-Arg
(Baskaran et al., 1997a).  To understand the action of c-Abl, it is important to
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understand the context in which it is activated:  c-Abl requires its non-specific
DNA binding domain for high stoichiometric phosphorylation of the CTD, but
since its DNA binding domain is non-specific, c-Abl is probably recruited to
DNA by its interacting partners.  Nuclear c-Abl can only be strongly activated
in response to DNA damage during the S/G2 phases of cell cycle, when RB is
inactive (Wang and Ki, 2001).  The cell cycle regulation of c-Abl is implemented
by the RB protein (Welch and Wang, 1993) , which binds and inhibits both E2F-1
and c-Abl until it becomes deactivated by cyclin-dependent kinases or caspases
(Wang and Ki, 2001).   This predicts a scenario where c-Abl is specifically
recruited to E2F-1-regulated promoters, enabling it to easily phosphorylate the
Pol II CTD, and other transcription factors in response to a specific type of
cellular stress, in a cell cycle dependent manner (Depicted in Fig. 3).
1.8 The RNA polymerase II CTD and the processing of pre-
mRNA
The correct processing of pre-mRNA has long been shown to be a pre-
requisite for efficient transcription (Edery and Sonenberg, 1985; Hart et al., 1985;
Jove and Manley, 1982).  That these different processes require RNA
polymerase II suggested an intimate connection between the transcription
complex and the RNA processing machinery (Hirose and Manley, 2000).  Of the
three known RNA polymerases in eucaryotic cells, only Pol II transcripts
undergo splicing of introns, 5´end capping, and polyadenylation.  A major
distinction between RNA polymerase II and other polymerases is the presence
of the CTD.  Interestingly, the size of CTD apparently increases with complexity
of an organism, which may also correlate to their requirement for pre-mRNA
processing.
mRNA capping
Messenger RNA production in vivo occurs co-transcriptionally and is
exclusive to Pol II transcripts.  The CTD of Pol II is required for the capping,
splicing and polyadenylation of pre-mRNAs in vivo.  The 5´ capping of mRNA
occurs shortly after transcription initiation, when the nascent RNA is
approximately 25 bases long (Coppola et al., 1983).  Phosphorylation of the CTD
occurs soon after initiation and is essential for recruitment of the capping
enzyme complex.  The capping enzyme binds CTD heptapeptides
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phosphorylated at either serine-2 or serine-5, but only serine-5 phosphorylation
stimulates guanyltransferase activity.  Capping is performed by a series of three
enzymatic activities:  RNA triphosphatase removes the γ-phosphate of the first
nucleotide of the nascent RNA; RNA guanyltransferase transfers GMP to the
resulting diphosphate end; RNA (guanine-7-) methyltransferase then adds a
methyl group to the N7 position of the cap guanine, to form the
m7G(5´)ppp(5)N cap.
Splicing
Although splicing reactions can be reconstituted in vitro using pre-
transcribed RNA and splicing competent cell extracts, the localisation and
orchestration of splicing events in vivo appears to require CTD.  Components of
the spliceosome, a large macromolecular complex of snRNPs and members of
the serine/arginine-rich (SR) protein family, can be found localised to active
sites of transcription (Zhang et al., 1994).  The hyperphosphorylated form of
RNA polymerase II (IIO) has been found associated with splicing factors, and
only this form has been detected in active spliceosomes.  Co-localisation of
splicing factors and Pol II in vivo is not observed in cells expressing a
polymerase with a truncated CTD (Misteli and Spector, 1999).  The Pol IIO form
co-immunoprecipitates with splicing factors, including SR proteins, further
supporting a role for CTD in the coordination of splicing events.  Additionally,
several phospho-CTD binding proteins identified so far, also contain the SR and
RRM domains that are characteristic of many splicing factors (Morris and
Greenleaf, 2000).
3´-cleavage and polyadenylation
The polyadenylation of the 3´-end of nearly all eucaryotic pre-mRNA
appears to be a requirement for the correct termination and the precise
definition of the 3-end.  3´-end formation is a two step process that is tightly
coupled in vivo.  First, endonucleolytic cleavage of the pre-mRNA occurs, 10 to
30 nucleotides downstream of the sequence motif, AAUAAA, followed by
extension of the upstream fragment by poly(A) polymerase (PAP).  At least 12
different proteins are involved in this process in vivo , forming four multi-
subunit proteins, cleavage polyadenylation specificity factor (CPSF), cleavage
stimulation factor (CstF), and two cleavage factors (CF I; CF II) (Hirose and
Manley, 2000).  CPSF and CstF function to recognise and define the poly(A) site
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and its surrounding region while CF I and CF II are required for the cleavage
reaction.  The CTD of RNA polymerase II appears to be essential for this
reaction in vivo.  Both CPSF and CstF have been shown to bind CTD, however,
unlike capping and splicing factors, the phosphorylation status of the CTD does
not affect their binding.  Although CTD may act as a scaffold for these factors, it
appears that the recruitment of these factors may occur through the initiation
complex:  the general transcription factor TFIID purifies with CPSF (Dantonel
1997); a transfer of CPSF from TFIID to Pol II during initiation is seen in
reconstituted transcription assays.  An extensive analysis of the involvement of
CTD in this reaction by (Ryan et al., 2002) further supports its role as a scaffold.
Their data suggest the principle determinant of CTD activity in 3´-cleavage is its
length.  The non-consensus repeats 30-37 of the eucaryotic CTD may play a
slightly more important role than other heptads in CTD cleavage activity, but
are not essential since a full length CTD composed of only consensus repeats
still has 80 % activity compared to wtCTD.
1.9 Termination of transcription
The termination of transcription is dependent on the presence of a
functional poly(A) signal (Proudfoot, 1989).  The poly(A) signal not only directs
3´-end processing, but also the termination of transcription.  The mechanism by
which this occurs is still cause for speculation.  Models suggested to explain the
coupling of 3´-end processing to termination fall in to two categories: (i) a
cleavage-dependent ('torpedo') models where cleavage of the transcript at the
poly(A) site initiates termination by promoting degradation of the 3´-product
still attached to the elongating polymerase, and (ii) cleavage-independent ('anti-
terminator') models, in which recognition of the poly(A) site invokes some
conformational change in the transcription complex that makes it termination
competent (Proudfoot, 1989).
Although the poly(A) site signal is a definite requirement for
termination, 3´-end processing still occurs some distance downstream of the
point at which it was transcribed (Tran et al., 2001).  A model has thus been
proposed in which the poly(A) site is held to the CTD via interaction with the
CPSF and CstF factors (Dichtl et al., 2002), and the non-coding, nascent RNA is
looped out between the CTD-associated RNA processing factors and the Pol II
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RNA exit channel (Cramer et al., 2001; Proudfoot et al., 2002).  The cleavage of
the emerging RNA is suggested to produce an entry site for 5´-3´exonucleases
to degrade the downstream cleavage product.  The exonuclease may then ´catch
up´ with the elongating polymerase, eventually disturbing the RNA:DNA
hybrid and causing termination.  Pause sites present downstream of the poly(A)
site, originally thought to be termination sites, are non-essential but may
enhance poly(A) site recognition and cleavage by slowing the elongation rate of
Pol II (Proudfoot et al., 2002).
1.10 Transcription and the DNA damage response
DNA damage is a major problem for every organism:  genetic damage
prevents a cell from correctly reading and replicating its genome.  Damage may
result from environmental agents, such as high frequency, electromagnetic
radiation (ionising radiation: IR) and reactive chemicals, as well as from
metabolic by-products such as reactive oxygen intermediates.  Damage may
threaten survival of a cell, or lead to mutations that are then passed to the next
generation.
Such mutations have certainly resulted in survival advantages, through
the modification of coding or controlling regions in the DNA.  On the other
hand, these mutations may lead to deregulation of certain processes, for
example, proliferation, which in multicellular organisms results in cancer.  To
maintain genomic stability, cells have developed a variety of mechanisms to
detect and respond to DNA damage, involving complex signalling pathways
that coordinate repair and cell fate decisions.
Although general mechanisms exist, it has become clear in recent years
that specific pathways exist for the sensing and relaying of DNA damage
signals, dependent on the specific type of DNA damage (Abraham, 2001).  One
of the consequences of DNA damage is a change in the regulation of gene
transcription.  Despite an observed general reduction in transcription, the
transcription of some genes involved in cell cycle control and apoptosis, is up-
regulated.
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1.10.1 The p53 tumour suppressor
The tumour suppressor protein and transcription factor, p53, is activated
following exposure to DNA-damaging agents, by a post-translational
mechanism that confers its stability.  p53 tetramises and binds to promoters,
activating the transcription of its target genes, which include p21, mdm2, BAX
and GADD45 (detailed list: (Zhao et al., 2000) (Reviewed in:  Levine, 1997;
Vogelstein et al., 2000).  Under certain conditions p53 induces cell cycle arrest,
and under others programmed cell death (apoptosis).  The mechanism by
which p53 decides cell fate is not entirely understood, but an allosteric model
has been proposed, where p53 binds with a greater affinity to promoters of cell
cycle arrest genes (for example, p21), and to the promoters of apoptosis
inducing genes with a lower affinity.  This model implies that low-level
expression of p53 induces cell cycle arrest, whereas a high level of p53
expression (resulting from serious damage) may induce apoptosis (Chen et al.,
1996; Hupp and Lane, 1994a; Hupp and Lane, 1994b; Ludwig et al., 1996).  p53
has a very short half-life as a result of its continuous degradation by the
ubiquitin-proteasome machinery (Maki et al., 1996).  This degradation is
mediated by the Mdm2 E3 ubiquitin ligase, which binds to the transactivation
domain of p53 (Honda et al., 1997; Honda and Yasuda, 1999).  Interestingly,
transcription of the mdm2 gene is strongly activated by p53, creating a negative
auto-regulatory feedback loop (Barak et al., 1993; Momand et al., 2000).
Stabilisation is achieved by blocking the interaction of p53 with Mdm2
through post-translational mechanisms.  The ARF tumour suppressor regulates
p53 by directly blocking the E3 ligase activity of Mdm2 and transporting it to
the nucleolus, thereby preventing its interaction with p53 (Honda et al., 1997;
Honda and Yasuda, 1999; Tao and Levine, 1999a; Tao and Levine, 1999b; Weber
et al., 1999).  p53 is target for a number of modifying enzymes, including
kinases and acetylases.  Phosphorylation of p53 on serine 20 has been shown to
increase its stability by disrupting its interaction with Mdm2 (Shieh et al., 2000),
and serine 15 phosphorylation enhances its transactivation potential through
recruitment of the HAT, p300 (Dumaz and Meek, 1999; Lambert et al., 1998).
The preferential phosphorylation of certain residues by the different kinases is
suggested to modify the function of p53, and one modification may permit
further modification by another enzyme (Dumaz et al., 1999).  Different types of
cellular stress activate distinct protein kinases and acetylases, which modify p53
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at different residues and might partly explain why the p53 transcriptional
response is dependent on the type of cellular stress (Zhao et al., 2000).
1.10.2 RNA polymerase II in the detection and repair of damage
The cellular response to DNA damage has been extensively researched,
however, the mechanisms by which damage is detected still remain enigmatic.
The time required for the induction of a DNA damage response is extremely
short, suggesting an extremely sensitive detection mechanism.  Since
transcription complexes are constantly present on the DNA it has been
suggested they may have a dual role in both the detection and repair of DNA
damage.  Indeed, the basal transcription factor TFIIH, required for initiation
and early transcription elongation of RNA polymerase II, contains the XPB and
XPD proteins, which play an essential role in nucleotide excision repair
(Schaeffer et al., 1993; Svejstrup et al., 1995).
It has been demonstrated that transcription inhibition serves to trigger the
induction of p53 (Ljungman, 1999; Ljungman and Hanawalt, 1996; McKay et al.,
1998), and prolonged inhibition of mRNA synthesis may induce apoptosis
(McKay et al., 2000; McKay et al., 1998).   Experiments by Ljungman and co-
workers compared the induction of p53 in response to inhibitors of RNA
polymerase II CTD phosphorylation, and that induced by DNA damaging
agents.  Both resulted in accumulation of p53, however, only agents that
inhibited the elongation phase of transcription (UV, actinomycin D) resulted in
phosphorylation of p53 at serine 15, and acetylation at lysine 382 (Ljungman et
al., 2001; Ljungman et al., 1999).  This suggests that blockage of the transcription
elongation phase results in the activation of different signalling pathways.
An elongating RNA polymerase II will stall at DNA lesions and recruit the
transcription-coupled repair (TCR) apparatus (de Laat et al., 1999).  Stalling of
RNA polymerase II also activates other mechanisms involved in the response to
genotoxic stress, including induction of p53.  Interestingly, there appears to be
different mechanisms for detecting, and responding to different types of
genotoxic insult. UV irradiation (254nm) induces bulky DNA lesions
(Friedberg, 1995) and gamma/ionising irradiation (IR) induces double strand
breaks.  Stabilisation of p53, a nuclear event, occurs after both treatments, but
two distinct signalling pathways are activated.  UV also induces membrane-
associated signalling proteins that lead to the activation of the transcription
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factors AP1 and NFkB (Devary et al., 1992; Liu et al., 1996). The response to IR
however, requires the ataxia telangiectasia mutated (ATM) protein, a member
of the phosphoinositide 3-kinase related kinase family (PIKK), that play critical
roles in early signal transmission through cell cycle checkpoints (Reviewed in
(Abraham, 2001).  ATM accelerates the response and repair of such damage.
Ataxia-telangiectasia (A-T) patients are extremely sensitive to IR, and ATM -/-
cells exhibit a delayed p53 response following IR exposure (Kastan et al., 1992).
How a double stranded break is recognised is not yet known, but many data
suggest the Rad group of checkpoint proteins to be key players (O'Connell et
al., 2000).  It is not clear how the protein kinase activity of ATM is activated.
One possibility is that reactive oxygen species (ROS), or DNA double-strand
breaks produced following a genotoxic insult like IR exposure, may result in a
post-translational modification of ATM that stimulates its kinase activity.
ATM has been identified in complexes containing a broad range of
proteins with clear links to cell cycle, DNA repair and human chromosomal
instability syndromes.  The elucidation of ATM substrates provides clues to its
function.  ATM forms part of the BRCA1 (breast cancer susceptibility antigen
1)-associated genome surveillance complex (BASC), along with the mismatch
repair proteins, MLH1, MSH2 and MSH6, the Mre11-Rad50-NBS1 complex, that
is involved in the recombinatorial repair of DNA double strand breaks, and the
Bloom's syndrome helicase (BLM).  The phosphorylation of complex
components by ATM, and other checkpoint kinases (for example, hChk2), is
thought to co-ordinate the recruitment and activation of the repair machinery
(Abraham, 2001).  The roles of other substrates is, however, not so apparent.
1.11 ATM and the regulation of cell cycle
ATM has been shown to be involved in cell cycle regulation at the G1/S
checkpoint, through p53-mediated induction of the cyclin-dependent kinase
(CDK) inhibitor p21.  Cell cycle progression in to S-phase requires the
inactivation of the retinoblastoma protein (Rb), which is normally achieved
through its phosphorylation by cyclin-D-CDK4/6.  Rb belongs to the family of
so-called pocket proteins, which suppress E2F family proteins through binding
of their transactivation motifs.  The E2F proteins are S-phase specific
transcription factors, whose activity allows DNA synthesis to proceed
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(Reviewed in Helin, 1998).  Hypo-phosphorylation of Rb blocks the transition
from G1 to S-phase. Induction of the p53 response by ATM can thus lead to cell-
cycle arrest.
Interestingly, the Rb protein also binds, via its C-pocket, a portion of
the nuclear-localised, non-receptor tyrosine kinase, c-Abl (Welch and Wang,
1993), which is also an ATM substrate.  Rb binds the ATP-binding lobe of c-Abl,
thereby ensuring it may only be activated during S-phase (Wang, 1993; Wang
and Ki, 2001), or removal of Rb by another mechanism (Park et al., 2000). This
suggests a mechanism by which ATM may orchestrate phosphorylation of
substrates, in a cell cycle dependent manner.  Importantly, since E2F sites are
not present in the promoter region of every gene (Helin, 1998; Muller and
Helin, 2000), this interaction serves to recruit the c-Abl kinase to specific regions
of DNA, where it may among other functions, modulate the activity of certain
transcription factors (Gong et al., 1999).
1.11.1 The c-Abl tyrosine kinase
The c-abl, and related c-arg (abl-related gene) gene products contain
large N-terminal domains, homologous to those of the c-Src family of protein
tyrosine kinases.  However, in contrast, both proteins contain unique, large, C-
terminal domains of no homology to Src and relatively little to each other.  The
C-terminal domain of Abl is key to its function.  Extensive mutational analysis
has revealed an array of interaction motifs for regulatory proteins, three DNA-
binding domains (Kipreos and Wang, 1990; Kipreos and Wang, 1992; Van Etten
et al., 1994), F-and G-actin binding domains (Van Etten et al., 1994), three
nuclear-localisation signals (Van Etten et al., 1989; Wen et al., 1996) and one
nuclear-export signal (Reviewed in Van Etten, 1999).  The structural attributes
of c-Abl, and its ability to shuttle between cytoplasmic and nuclear locations
suggest a 'multi-tasking' function, as it functions both as an integrator and
effector of signalling pathways (Kharbanda et al., 1998).  This is supported by
the phenotype of mice where either c-abl was knocked out, or replaced by an
allele coding a C-terminal truncation with intact kinase activity.  Such mice are
born runted, have defects in osteoblast maturation, exhibit abnormal eyes,
frequent rectal prolapse, and defective spermatogenesis, resulting in shortened
survival. (Hardin et al., 1995; Hardin et al., 1996; Li et al., 2000; Schwartzberg et
al., 1990; Schwartzberg et al., 1991; Wong et al., 1995).
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The localisation of c-Abl has been shown to have a profound effect on its
function.  Nuclear c-Abl is cell cycle regulated, through sequestration by Rb,
and can be activated in S-phase following DNA damage (Kharbanda et al.,
1995). In contrast, cytoplasmic c-Abl is not affected by cell cycle or DNA
damage, but instead responds to changes in cell adhesion (Lewis et al., 1996).
 The c-abl gene was first identified due to its homology to the transforming
gene of the Abelson murine leukaemia virus (v-abl) (Abelson and Rabstein,
1970; Goff et al., 1980), and has since been identified in several leukaemia-
associated fusion proteins, most notably the t(9;22) Philadelphia chromosome,
that results from aberrant chromosome translocations.   Importantly, all the
transforming Abl proteins are exclusively cytoplasmic, and transformation of
fibroblasts is enhanced through the membrane-anchoring, myristylation of
Abl's N-terminus.  Conversely, activation of nuclear c-Abl is associated with
growth arrest and apoptosis.  This difference in nuclear and cytoplasmic
function, was elegantly demonstrated by Wang et al., who forcibly localised
active Abl kinase to the cytoplasm or nucleus, with drastically different
consequences (Wang, 2000).
Until recently, the nuclear mechanisms of c-Abl induced growth arrest
and apoptosis were completely enigmatic.  c-Abl was shown to require its SH2
and kinase (SH1) domains to mediate its cytostatic and cytotoxic effects,
indicating that interaction with one, or more of its substrates is required (Goga
et al., 1995; Wen et al., 1996).  Activated c-Abl has been reported to
phosphorylate, and down-regulate components of the DNA repair machinery,
including Rad51 (Yuan et al., 1998), and DNA-PK (Kharbanda et al., 1997),
however, the relevance of this is not understood since c-abl -/- cells exhibit no
defined cell cycle or repair defects (Liu et al., 1996).  Other substrates include
transcription factors:  c-Abl can complex with the transcription factors CREB
and E2F-1 to modulate c-myc transcription (Birchenall-Roberts et al., 1997); in S-
phase c-Abl can phosphorylate the CTD of RNA polymerase II, a step which
may affect gene-specific initiation, elongation of transcription, and pre-mRNA
processing (Baskaran et al., 1997a; Baskaran et al., 1996; Baskaran et al., 1993;
Baskaran et al., 1999; Oelgeschlager, 2002)
Increasing evidence implicates activated nuclear c-Abl in pro-apoptosis
signalling.  c-Abl was found to phosphorylate and stabilise the p73 protein, a
p53-family member involved in cell fate decisions (Gong et al., 1999) (For
review see Yang et al., 2002), and in the inhibition of the anti-apoptotic
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transcription factor NFkB (Kawai et al., 2002).
1.11.2 The role of c-Abl in transcription
The DNA binding domain of c-Abl is regulated by the cdc2 kinase.
During early mitosis, cdc2 hyperphosphorylates c-Abl on multiple threonines
and serines, including serines 852 and 883 of the DNA-binding domain, thereby
inhibiting its DNA binding (Kipreos and Wang, 1992).  The DNA binding
domain of c-Abl can recognise a specific consensus sequence in DNA, similar to
those bound by HMG-like proteins such as LEF-1 and SRY, which bind
preferentially to 5’-AACAAAG, and 5’-A/TAACAA
A/T respectively (David-
Cordonnier et al., 1998a; David-Cordonnier et al., 1998b).  The Abl DNA
binding motif has a high proline content, and does not bear homology to any
known binding motif (David-Cordonnier et al., 1998a).  It was initially
described as binding the palindromic EP element of the HBV enhancer
(Dikstein et al., 1996; Dikstein et al., 1992), but this could not be confirmed by
other groups (Arcinas et al., 1994; Miao and Wang, 1996).  The role of this DNA
binding capacity has still not been established.
Since c-Abl has been shown to interact with transcription factors, its DNA
binding may function to position it correctly within the transcription complex,
thereby facilitating its phosphorylation of the RNA polymerase II CTD and
other substrates (Baskaran et al., 1997a; Baskaran et al., 1993; Baskaran et al.,
1999; Birchenall-Roberts et al., 1995; Birchenall-Roberts et al., 1997; David-
Cordonnier et al., 1998b; Yuan et al., 1999).  Recent work by the Wang lab
confirms this theory:  c-Abl phosphorylates p300/CBP in response to
doxorubicin induced DNA damage, thereby stimulating their activities.
Inhibition of acetyltransferase activity was shown to prevent Abl-induced
apoptosis, implicating activation of nuclear acetyltransferases as a requirement
for DNA damage-induced apoptosis (Costanzo et al., 2002).
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1.12 The purpose of this work
RNA polymerase II has been shown to be both a sensor and effector of
DNA damage:  the repair of DNA damage in actively transcribed regions is
much faster than that in inactive regions (Svejstrup, 2002).  The differential
phosphorylation of the Pol II CTD by specific, transcription-associated kinases
has been shown to affect transcription initiation, elongation and the processing
of RNA.  The last repeat of the CTD contains sites of interaction for the kinases
c-Abl, c-Arg and CKII – enzymes normally associated with proliferation and the
response to DNA damage.  Unlike other known CTD kinases, these interactions
might not occur universally and may thus have gene specific effects, either by
acting to affect the transcription complex directly, or by controlling the
recruitment of other factors to the polymerase.  The specific nature of these
interactions necessitates an in vivo system for their study.  The goal of this
project is therefore to establish an in vivo system to investigate the effect on
global cellular transcription, of removal, or mutation of the last CTD repeat.
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2. Results
2.0 A system for the conditional expression of Pol II CTD
mutants in vivo
To determine the importance of the mammalian CTD 'last repeat', a vector
containing the full length, haemagglutinin-(HA)-tagged, mouse RPB1 gene was
adapted to permit easier manipulation of the RPB1 CTD coding sequence.  The
introduction of a multiple cloning site (MCS) immediately before the stop
codon enables extension or truncation of the CTD, however, its own presence
results in a 21 bp insertion encoding a further seven amino acids.
Given the repetitive nature of the CTD, the possibilities for manipulation
within its sequence are limited.  Fortunately, some non-consensus repeats like
repeat 49 contain unique restriction enzyme sites.  Figure 4. depicts the changes
in the amino acid sequence of three CTD mutants, LS*49+52, LS*49M+52 and
LS*49+50, that were produced by truncation of the sequence to 49 repeats
followed by the addition of sequence for either the endogenous repeat 50, or 52.
The mutant LS*49M+52 truncates the non-consensus repeat 49 to the consensus
repeat length of seven amino acids.  Since the importance of repeat 49 is not
known, this mutant will control that any effects seen are resulting from
mutation of the last repeat, and not a consequence of disturbing the region
around this non-consensus repeat.
An additional mutant was produced by cloning of the cDNA for the
enhanced, green fluorescent protein (EGFP) in to the MCS (Fig. 4B).  In addition
to producing a control for expression and localisation, the EGFP domain may
also impede interactions with the last repeat.  24h following induction, the
EGFP labelled polymerase is seen distributed throughout the entire cell (Fig. 5).
Further culture in the presence of α-amanatin may assist its nuclear importation
by inducing the degradation of the endogenous Pol II – 48h later almost all
EGFP label is nuclear, concentrated in speckles and absent from the nucleolus
(data not shown).
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Figure 4. Overview of the amino acid composition of CTD mutants.  (A) The
multiple cloning site (MCS) region of the mutant LS*wtMCS produces an
extension of seven amino acids to the wild type last repeat. Unique
restriction enzyme sites in the DNA coding sequence for the non-consensus
repeat 49 and in the MCS region allow this region to be removed and
replaced.  Mutants were produced ending in either the 52nd (last-) or 50
repeats.  An additional mutant, ending in repeat 52, but lacking the non-
consensus, three amino acid extension of repeat 49 (designated 49M) was
also produced. (B) The MCS allows insertion of other sequences to produce
fusion proteins, such as with the EGFP localisation tag.
The Pol II LS (Rpb1) sequence used contains a point mutation (Asn793Asp)
conferring α-amanatin resistance (*) (Bartolomei and Corden, 1987) to our
recombinantly expressed Pol II LS (Pol II LS*).  By growing cells in the presence
of α-amanatin for 24 hours, the endogenous Pol II is effectively, chemically
´knocked-out´, thereby allowing the properties of our mutant polymerases to be
examined in vivo.
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Figure 5. Localisation of exogenously expressed Pol II LS*EGFP in Raji cells.. α-
amanatin [2µg/ml] was applied to cell cultures, 24h following the removal
of Tc.  Cells were then cultured for a further 48h to allow stabilisation of the
expression and distribution of the EGFP tagged Pol II before analysis by
UV microscopy.
2.1 Establishment and characterisation of cell lines conditionally
expressing Pol II CTD-mutants
The vector used, ´LS*mock´, contains several important features for the
stable transfer and conditional expression of our mutants into cell lines (Fig. 6).
Many transfection systems involve the random integration of vector DNA in to
the host genome.  This creates problems associated with so-called 'position
effects':  endogenous regulatory elements in the region of integration may
provide unwanted positive, or negative effects on the transcription of
introduced sequences.  Our vector overcomes this effect by utilising the
replication origin of the Epstein-Barr virus (EBV-oriP).  This confers the
advantage that it is episomally maintained, and does not integrate into the
genome of human cells expressing the EBV-nuclear antigen 1 (EBNA1).
Episomes replicate like extra chromosomes, simultaneously with the genomic
DNA.  The lack of position effects removes the need to produce and test many
different cell lines for every different vector, allowing cell lines instead to be
produced as a ´batch-culture´.
Conditional expression of RPB1 is achieved through control of its
promoter by a tetracycline-response element (TRE):  the E. coli tetracycline- (Tc)-
regulated operator (tetO7) combined with a minimal portion of the EBV-latent
membrane protein 1 (LMP1) promoter.  The LS*mock vector also contains, and
constitutively expresses a fusion protein (TcTA) of the E. coli Tc-repressor with
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the transactivator (TA) domain of the herpes virus protein, VP16.  The TcTA
used in this system binds its operator only in the absence of Tc, thus, removal of
Tc results in its binding to, and activation of the TRE (Gossen and Bujard, 1992).
The vector constructs LS*mock (empty vector), LS*wtMCS, LS*wtEGFP,
LS*49+52 and LS*49+50 were transfected into the Burkitt’s Lymphoma cell line,
Raji and selected in the presence of Tc and G418 over several weeks to establish
stable, polyclonal cell lines.
Figure 6. Schematic representation of the expression vector.  The mouse
α−Amanatin-resistant RPB1, and CTD mutants thereof were cloned in to
the vector LS*mock.  Key features:  HA, haemagglutinin tag; H, position of
the point mutation that confers α−Amanatin resistance; CTD, carboxy-
terminal domain; EBV-oriP, a replication origin of the Epstein-Barr Virus
(EBV) for episomal replication of the plasmid; TcTA, tetracycline (Tc)-
regulated transactivator that binds to the tetO7-sequence of the Tc-response
element (TRE) contained in the EBV minimal promoter of the latent
membrane protein 2A (LMP) in the absence of tetracycline; NEO, neomycin
(G418)-resistance gene; AMP, ampicillin-resistance gene
2.1.1 Removal of the last CTD repeat induces its IIb form
The tight regulation of expression through Tc is demonstrated in figure
7A.  Stably transfected cell lines were grown in the presence or absence of Tc for
24 h before protein extraction and Western blot analysis.  The HA-tagged,
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recombinant polymerases are only detected in the absence of Tc.  The hyper-
(IIo) and hypo- (IIa)-phosphorylated forms of Pol II LS* are visible for each
mutant.  The truncated mutant LS*49+52 appears like LS*wt (data not shown).
The LS*wtEGFP mutant migrates at a slower rate due to its greater size.  The
addition of EGFP appears to have little effect on the proportions of the IIa and
IIo forms.  In contrast however, the mutant lacking the endogenous last repeat
(LS*49+50) exhibits reduced levels of the IIo form, almost proportional to the
appearance of a truncated form, Pol IIb (Christmann and Dahmus, 1981).  This
suggests that the IIo form of this mutant might be preferentially degraded.
Figure 7. Analysis of tetracycline-regulated recombinant Pol II LS* expression
and function.  (A) Tetracycline (Tc)-regulatable expression of stably
transfected Pol II LS* mutants in the Burkitt’s lymphoma cell line, Raji.
The recombinant proteins have been identified using the high affinity, anti-
HA antibody 3F10. (B) Raji cell lines were grown in the presence or
absence of Tc for 24h, after which, α-amanatin [2µg/ml] was added to the
indicated samples and incubated a further 24h.  Cells were exposed to a heat
shock for 2h at 43°C before harvesting of their RNA.  10µg of total RNA
from each sample was probed for levels of hsp70A RNA using a
complementary radioactive probe. The 28S and 18S RNA bands, stained
with ethidium bromide, provide a control for equal loading.
The α-amanatin-resistant phenotype of our mutants allows them to
functionally replace the endogenous Pol II when grown in the presence of α-
amanatin (Meininghaus et al., 2000).  Despite the high affinity of α-amanatin for
Pol II (Kd≈10
9M), the inhibition and the degradation of Pol II LS is very slow.
The limiting step appears to be the take up of α-amanatin by cells.  For this
reason, an incubation time of 24 h is required before mutant function can be
analysed.
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2.1.2 A mutant lacking the last repeat exhibits a reduced ability to
transcribe the hsp70A gene, and cannot sustain cell viability
The heat-shock inducible, hsp70A gene, was used to assess the mutants for
their ability to transcribe a chromatin template (Fig. 7B).  In the presence of Tc
alone, the endogenous Pol II produces a strong induction of hsp70A RNA in
response to heat shock.  In the presence of α-amanatin and Tc, no signal is
observed since no α-amanatin resistant polymerase is present.   In the presence
of α-amanatin and absence of Tc, both mutants transcribe hsp70A in response to
heat shock.  The signal seen for both polymerases is weaker compared to that of
the endogenous Pol II.  Additionally, the signal produced by LS*49+50 was seen
to be consistently weaker than that produced by LS*49+52.  This may be a result
of the large proportion of this mutant converted to the inactive IIb form.
Pol II LS* mutants able to support all essential Pol II functions should be
able to support growth and proliferation of cells in the presence of α-amanatin.
Previous work has shown that cells expressing Pol II LS*wt under α-amanatin
first undergo a selection, perhaps to become accustomed to expression levels
and the degradation of the endogenous polymerase.
To compare the abilities of LS*49+50, LS*49+52 and LS*wtEGFP to that of
LS*wtMCS, cells were induced to express their mutants 24 h before the addition
of 2mg/ml α-amanatin (Day 0).  The viability of cells was assessed regularly
over a period of 40 days, during which time cultures were split and medium
exchanged as necessary, to maintain the viable cell number at ≈5x105 cells/ml
(Fig. 8).  The cell line, LS*mock, expresses no polymerase, and thus possesses no
α-amanatin-resistance, was included as a control.  Inhibition of Pol II has been
shown to induce stabilisation of mRNA, which may account for the
unexpectedly long time for non-resistant cultures to reach 0 % viability
(Meininghaus M., personal communication).  The mutants LS*wtMCS, LS*49+52
and LS*wtEGFP all sustain the viability of Raji cell lines, which, following the
initial crisis phase returns to between 80 and 90 percent.
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Figure 8. Viability of Raji cell lines in the presence of α-amanatin. (A) Stably
transfected cell lines were grown in tetracycline (Tc)-free medium to induce
the expression of the Pol II LS* CTD mutants.  24h after induction, α-
amanatin was given to the medium [2µg/ml]. A control cell line containing
an empty expression vector, `Mock´, was included.  Tc was reapplied to
LS*49+52 following recovery at day 27. (B) Comparison of cell lines Mock
and LS*wt EGFP resistance to α-amanatin, and the effect of Tc re-addition
at day 31.  These data are representative of several repeated experiments.
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The viability experiment shown in figure 8B is a representative example of
the results from several studies.  As shown for the Raji LS*wtEGFP cell line, re-
addition of Tc (day 33) represses expression of the mutant Pol II LS*, thereby
removing resistance to α-amanatin and resulting in the loss of viability.
2.2 Advanced mutational analysis of the last repeat
The mutants tested in the previous experiments indicate that elements
contained in the last repeat of Pol II CTD are important for its stability and cell
viability.   This element is apparently undisturbed by the addition of a small,
random amino acid sequence (LS*wtMCS), or a much larger domain
(LS*wtEGFP).
The last repeat has been identified as the essential recognition site for the
tyrosine kinases c-Abl and c-Arg (Baskaran et al., 1997a; Baskaran et al., 1996),
and contains two consensus phosphorylation sites for CKII.  A series of further
mutants were therefore produced, to better identify the important elements
within the last repeat (Fig. 9).  Two mutants were produced with one point
mutation, resulting in the change of a serine to an alanine in either one of the
two CKII sites (LS*49+52 S9A; LS*49+52 S13A), and also a double point mutant
where both sites were mutated (LS*49+52 S9/13A).  To disturb c-Abl
interaction, a nonsense mutant was produced where the amino acid sequence of
the last repeat was randomly reconstituted, while still preserving two CKII sites
(LS*49+NS52).  Additionally, a mutant was produced, containing repeat 50,
plus a ten amino acid sequence known to be the c-Abl recognition motif in
ATM (LS*49+50ATM).  Whether this short motif can indeed interact with c-Abl
in this context is not known, but nevertheless it provides another useful control:
alike the wt last repeat, a non-consensus repeat (YSPTSPG) is flanked by an
additional ten amino acids (DPAPNPPHFP).  This mutant also contains one
potential CKII site.
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Figure 9. Overview of RNA polymerase II CTD mutants.  Expression vectors were
produced for the above CTD mutants.  With the exception of LS*wt MCS,
all mutants contain just 49 of the original repeats, plus the wild-type final 17
amino acids, or mutant thereof.  The addition of a multiple cloning site to
the wild type (wt) sequence results in the addition of seven extra amino
acids.  Green boxes signify potential caesin kinase II (CKII) sites, based on
the consensus recognition sequence S/TxxD/E.  Residues labelled red
denote point mutations from the original sequence.  Mutant LS*49+NS52
contains the wt final 17 amino acids in a scrambled (non-specific) order.
Mutant LS*49+50ATM contains repeat 50 fused with the c-Abl interaction
motif of ATM.
2.3 Characterisation of last repeat mutants in different Burkitt’s
Lymphoma cell lines
Stable cell lines were produced for each mutant in Raji, and as a control,
the mutants LS*49+50, LS*49+52 and LS*49+NS52 were also stably transfected
in to two other EBV+ Burkitt’s lymphoma cell lines, BL29 and Elijah.
Expression analysis in these cell lines (Fig. 10A) reveals a similar pattern to that
seen in Raji (Fig. 10B):  mutants where the final repeat is absent, or severely
disturbed (LS*49+50; LS*49+NS52), result in the appearance of the truncated Pol
IIb form, thus demonstrating that this phenomenon is not cell line specific.
Unfortunately, due to their extreme sensitivity to stress, production of these cell
lines was difficult, and those stable lines achieved could not be used beyond
simple expression studies because of their sensitivity to α-amanatin.
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Figure 10. Expression of LS* CTD mutants in Burkitt’s lymphoma (BL) cell lines.
(A) Expression of Pol II LS* mutants containing or lacking the wt CTD
final repeat in the stably transfected EBV+, BL cell lines, BL29 and Elijah.
(B) Expression of Pol II LS* mutants containing wt, point-mutated, or
scrambled final repeat in the EBV+, BL cell line, Raji.
2.4 Further characterisation of last repeat mutants in the Raji
cell line
2.4.1 Disruption of the last repeat, but not the disruption of its CKII
consensus sites, results in the appearance of the IIb form
Stable Raji cell lines were achieved for all the mutants.  No apparent
difference in expression pattern is seen between mutants with an intact last
repeat and those with CKII site mutations (Fig. 10B).  This suggests that these
mutations are not important for induction of the IIb form.  Some motif present
in the wt last repeat, and absent in the mutants LS*49+50, LS*49+52 and
LS*49+NS52, must protect the RNA Pol II LS from destruction.  The Pol IIb
form was originally thought to be a novel form Pol II that lacks activity
(Christmann and Dahmus, 1981; Corden et al., 1985).  However, it is
noteworthy that the IIb form results from one single cut, suggesting a specific
protease, rather than a general proteasome activity to be responsible.  The
existence and role of this form in vivo has not yet been described.
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2.4.2 Only mutants containing the last repeat become heavily tyrosine
phosphorylated following IR
Raji cell lines expressing various CTD mutants were exposed to IR, a
stimulus known to induce the phosphorylation of tyrosines in the CTD
(Baskaran et al., 1993), by the c-Abl tyrosine kinase (Baskaran et al., 1996).  Since
this interaction requires the Pol II LS last CTD repeat (Baskaran et al., 1999),
removal of this domain should prevent an increase in CTD tyrosine
phosphorylation in response to IR.  Since the levels of phospho-tyrosine in vivo
are low in comparison to other phospho-amino acids, cells must be incubated in
the presence of phosphatase inhibitors one hour prior to irradiation to assist
detection.  Immunoprecipitation of nuclear extracts was performed to purify
the HA-tagged Pol II LS mutants, and reduce the phospho-tyrosine background
to enable visualisation of specific CTD tyrosine phosphorylation.
Figure 11. Tyrosine phosphorylation of Pol II LS* CTD mutants following IR.
Cells expressing Pol II LS* CTD mutants were irradiated with 8 Gy IR in a
Gammacell, then harvested 1h later.  Immunoprecipitation was performed
using the anti-HA antibody, 3F10. Western blots were stained with the anti-
pY antibody, C38, then stripped and re-probed with the anti-HA antibody
3F10 to confirm the presence of the proteins.
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The panel of mutants compared differ in their number of CTD repeats
(Fig. 11:  from left to right: 5,31,50,50 and 52 repeats).  However, LS*49+50 is the
only mutant not containing the last CTD repeat.  The amount of tyrosine
phosphorylation seen for some mutants is greater than others, and does not
appear proportional to the number of repeats present.  This may be a result of
disproportionate loading, as seen for LS*∆31, or incomplete inhibition of
phosphatases in some samples.  The same blot was re-probed with anti-HA
antibody to control loading:  all mutants appear loaded in sufficient quantity.
In confirmation of earlier data (Baskaran et al., 1999), the mutant lacking the last
CTD repeat, LS*49+50, was the only not to demonstrate increased tyrosine
phosphorylation in response to IR.  The length of number of CTD repeats
appears irrelevant:  tyrosine phosphorylation in response to IR being
dependent only on the presence of the last CTD repeat.  Additionally, since the
Pol II LS* is N-terminally tagged, the IIb form is also efficiently precipitated,
and migrates at a similar, or slightly faster rate than Pol II LS*∆5.  This suggests
that the site of proteolytic cleavage that yields the IIb form to be in close
proximity to the start of the CTD.
2.4.3 The appearance of the IIb form is not inhibited by a panel of protease
inhibitors
To investigate what protease may be responsible for the production of the
IIb form, Tc was removed from the Raji LS*49+50 cell line to induce expression.
After four hours, specific protease inhibitors were applied to the cell cultures
before harvesting 7 and 18 hours later.  Figure 12 shows the effects of the
different inhibitors on the formation of Pol IIb.  AAF-CMK is a specific inhibitor
of the tripeptidyl-peptidase II (TPII) enzyme that is up-regulated in BL cells
(Gavioli et al., 2001).  Proteasome inhibitors lactacystin and MG-132 have been
shown to inhibit the degradation of Pol II following UV irradiation (Ratner et
al., 1998).  Proteases involved in the regulation of cell proliferation,
differentiation and apoptosis were tested:  ALLM (calpain inhibitor II),
calpeptin, and calpain inhibitor III are inhibitors of the calpain family of
cysteine proteases (Perrin and Huttenlocher, 2002); Caspase 8 has been shown
to proteolytically cleave Pol II LS (Lu et al., 2002), an inhibitor of which was also
included.  Earlier work in yeast demonstrated that treatment of samples with
the serine protease inhibitor phenylmethyl-sulfonyl fluoride (PMSF) completely
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inhibited the conversion of Pol B22o  (Pol IIa) to Pol B180 (Pol IIb) (Dezelee et al.,
1976).  A cocktail of protease inhibitors (Roche) directed against serine, cysteine
and metalloproteases, as well as calpains were also tested.  In addition to
protease inhibitors, inhibitors of signalling pathways known to signal to the Pol
II CTD were also tested:  SKF-86002 inhibits osmotic stress and UV–induced
apoptosis by blocking p38 MAP kinase activation.  None of the inhibitors used
in this study appeared to be able to inhibit formation of the IIb form.
Figure 12. The effect of inhibitors on Pol IIB formation.  Expression of the
recombinant Pol LS*50 mutant was induced by removal of tetracycline. 2h
after induction the following inhibitors were applied at the indicated
concentrations: STI571, 20µM; AAF-CMK, 100µM; ALLM, 500µM;
Calpeptin, 100µM; Calpain inhibitor III, 500µM; Caspase 8 inhibitor I,
50µM.  Cells were harvested after 18h.  Proteins were identified using the
high-affinity, anti-HA antibody 3F10.
 The levels of IIa and IIb forms appear equal in all samples tested, except
in the sample treated with inhibitor cocktail, where no IIb form can be seen.
The low level of IIo form seen is to be expected, given that some time is
required for nuclear localisation, where the CTD phosphorylation required to
produce this form takes place.  The weak signals seen for samples treated with
MG-132, Caspase 8 inhibitor, or the inhibitor cocktail may result from the
general toxic effect these inhibitors have on cellular processes.  It is possible that
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some inhibitors are no longer active at the time point used (For example,
PMSF), however, the appearance of the Pol IIb form could not be inhibited even
at ten times the concentrations used here (data not shown).
2.4.4 Cell viability is severely affected by removal of the last repeat, but
not by its disruption, or mutation of its CKII sites
Raji cell lines expressing Pol II LS*wt have been previously shown to
tolerate growth in α-amanatin (Meininghaus et al., 2000).  To test the ability of
last repeat mutants to support growth and viability, their expression was
induced over a period of 24 h, before further culture in the presence of α-
amanatin (Fig. 13).  Cell number and viability were regularly recorded over a
period of more than 80 days.  As controls, two well characterised mutants,
LS*∆5 and LS*∆31, possessing only 5 or 31 CTD repeats, respectively
(Meininghaus et al., 2000), were also included in the analysis.  A similar pattern
is seen for all cell lines containing functional polymerases:  viability drops
steeply during the first 15 days of growth in the presence of α-amanatin,
followed by a crisis phase of little growth, and recovery after day 30.
The presence of α-amanatin appears to induce the stabilisation of cellular
mRNA by an as yet, unknown mechanism (Meininghaus et al., 2000).  This may
explain how in the first few days post-α-amanatin, a cell line lacking a fully
functional polymerase (LS*∆31) is still able to grow.   This phenomenon may
also explain the exponential growth seen for all other cell lines until day 8 (Fig.
13B).  Cellular stress due to the over- or under-expression of the exogenous
polymerases, or titration of transcription factors by the Tc-transactivator (TcTA)
and Pol II LS* itself may lead to sub-optimal gene expression.  The life span of
stabilised mRNAs is not known, and it is tempting to speculate that the crisis
phase that ensues until around day 30, results from a shortage of essential
mRNAs.  During this period, where little cumulative growth is observed, the
cells are effectively selected for those adapted to their new conditions.  The
increase in viability shortly before this point (day 25) results more likely from
the disappearance of dead cells than an increase in cell number (Fig. 13A).
As previously shown (Meininghaus et al., 2000), the transcription-
defective LS*∆5 mutant rapidly loses viability in the presence of α-amanatin,
exhibiting a kinetic similar to that of a control cell line containing empty vector
(LS*mock).  Cell lines LS*∆31 and LS*49+50, sustain cell viability for a period
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approximately three times longer than LS*∆5, but do not survive the crisis
phase and instead exhibit a sharp drop in cell number following day 8,
suggesting that they are incapable of replacing all the functions of the
endogenous Pol II LS.  Of all the last repeat mutants, only LS*49+50 is not
viable:  for all other mutants almost 90% viability is regained around day 50.  It
is theoretically possible that the recovery seen results from the endogenous
polymerase gaining α-amanatin resistance.  However, the inhibition of
exogenous Pol II LS* expression by re-application of Tc at day 51, resulted in α-
amanatin sensitivity and cell death.  In rare cases, re-addition of Tc failed to
have an effect on growth and viability.  Analysis of these cell lines revealed that
the exogenous, α-amanatin-resistant polymerase was still expressed:  control
through Tc had been lost (data not shown).  Two mutants containing the wt  last
repeat, LS*49+52 and LS*49M+52 (non-consensus repeat 49 is truncated to
consensus length), survived longer than the other mutants following Tc re-
addition.  This may indicate that last repeat mutants do in some way differ
from those with a wt last repeat.
The inability of the LS*49+50 mutant to sustain viability would not be
surprising if it were constantly being degraded.  However, mutants
LS*49+NS52 and LS*49+50ATM also exhibit induction of the IIb form.  Apart
from the slightly reduced length of its last repeat, it is not clear what differs
LS*49+50 from these other mutants.  If it is indeed the case, that the crisis phase
observed results from insufficient mRNA production, mutation of the last
repeat may affect transcription or pre-mRNA processing.  Since the last repeat
is the target of CKII and c-Abl, it may be the disturbance of these signal
pathways that is responsible for this phenotype.  However, the CKII mutants
exhibit no apparent phenotype, so it is more likely that interaction of c-Abl or
an as yet, unidentified protein with the last repeat is required.
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Figure 13. Growth and viability of Raji cell lines expressing Pol II LS*CTD
mutants in the presence of α-amanatin.  Stably transfected Raji cells were
induced to express Pol II LS*CTD mutants by removal of tetracycline (Tc)
from their growth medium.  24h after induction, α-amanatin was given to
the medium [2mg/ml].  Tc was reapplied to cultures exhibiting recovery at
day 51.  Viability and cumulative cell growth were assessed regularly over a
period of 84 days.
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2.4.5 Mutation of the last CTD repeat does not affect the specific
transcription of genes
Since c-Abl might only be recruited to some promoters, its influence on
transcription could be gene specific.  It has long been postulated that c-Abl may
influence transcription elongation (Baskaran et al., 1997a; Baskaran et al., 1999;
Bregman et al., 2000; Oelgeschlager, 2002).  To examine this possibility a DNA
array was used to assess the transcription of 1176 genes.  Due to the mRNA
stabilisation caused by α-amanatin treatment, the classic RT-PCR-based method
for gene expression analysis is not applicable.  This problem is overcome by
instead using the nuclear run-on technique to measure the polymerase density
on actively transcribed genes (Eick and Bornkamm, 1986; Greenberg and Ziff,
1984).  Figure 14 shows the results of such an experiment.  The cell lines
LS*49+52 and LS*49+50 were analysed and two fields, designated A and B, are
compared from the same array.
Despite repetition of this experiment several times, no reproducible
differences in gene expression between the two polymerases were seen.  The
only striking difference is the reduced signal intensity seen for the LS*49+50
mutant.  A similar difference was seen earlier in the ability of the two mutants
to transcribe the hsp70A gene (Fig. 7B).  The reason for this apparent weakness
is not clear, but may be a result of the degradation of Pol LS*49+50 to the
inactive IIb form.  That the transcription of any single gene was unaffected may
not be surprising:  if the kinases that act through the final repeat are only active
under certain circumstances, differences would not be seen in the absence of
stimulus; if these kinases work in synergy with other transcription factors for
their effect, no effect would be seen if they were not present.  Nuclei from non-
induced cell lines (+Tc), or a cell line expressing no α-amanatin resistant Pol II
(LS*mock), failed to demonstrate any specific Pol II transcription, indicating
that the transcription seen results from the α-amanatin resistant Pol II LS
mutants (data not shown).
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Figure 14. Comparison of global run-on transcription by Pol II LS* last CTD
repeat mutants.  Raji cells expressing mutants containing (LS*49+52), or
lacking the wt CTD last repeat (LS*49+50) were grown for 24h in the
presence of [2µg/ml] α-amanatin before isolation of nuclei.  Run-on
reactions were performed and the labelled RNAs hybridised to Clontech
Human Atlas 2.1 DNA arrays.  Regions A and B correspond to two
representative fields from the same array, for each mutant.
2.4.6 IR-induced tyrosine phosphorylation of the CTD does not affect the
specific transcription of genes
c-Abl is activated by the ATM protein in response to IR (Baskaran et al.,
1997b).  ATM normally also induces the tumour suppressor p53 (Lavin and
Khanna, 1999), however, in Raji cells p53 is disabled through mutation (Farrell
et al., 1991).  Thus, any changes in transcription seen following irradiation of
Raji cells, should be a direct result of c-Abl interaction with the CTD.  The
highest level of CTD tyrosine phosphorylation is seen approximately 1 hour
post-irradiation (Baskaran et al., 1993; Baskaran et al., 1999), at which point the
nuclear run-on analyses of nuclei from the two cell lines were performed.
Figure 15 indicates the actively transcribed genes in the cell lines LS*49+50 and
2.  Results 47
LS*49+52, before and 1 hour after exposure to IR.  Two representative fields, D
and E, from each array are shown for each cell line under each condition.
Again, the average signal intensity is weaker for LS*49+50 compared to
LS*49+52.  However, no reproducible difference could be seen in the activation
of specific genes, either between mutants, or in response to IR.
Figure 15. The effect of IR on active gene transcription in Raji cells.  Following 24h
induction of their respective recombinant Pol II LS* mutants, cells were
grown for a further 24h in the presence of [2µg/ml] α-amanatin before
exposure to 12 Gy IR, and isolation of nuclei 1 hour later.  Run-on reactions
were performed and the labelled RNAs hybridised to Clontech Atlas Human
Cancer 2.1 DNA arrays.  Regions D and E correspond to two representative
fields from the same array, for each mutant.  The expression pattern of
irradiated cells (+IR) is compared to a non-irradiated control (-IR).
2.5 Testing of cell lines for a response to IR
In order to ask questions about specific signalling pathways, it is
important to be asking questions in the correct system.  Since both CKII and c-
Abl are implicated in the response to DNA damage, the response in the cell line
to be used should be intact.  Since a loss of CKII activity would be lethal
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(Reviewed in Allende and Allende, 1995) , we can assume this enzyme functions
normally in these cells.  The Raji cell line, however, was first described in 1964
and has certainly evolved during its time in tissue culture.  By its nature, a
Burkitt’s lymphoma (BL) cell line with translocated c-myc t(8;14), the internal
apoptotic machinery has been compromised to permit its survival.  A mutation
in the tumour suppressor p53 (Farrell et al., 1991; Stenger et al., 1994) removes
its ability to tetramise, resulting in loss of this response:  p53 activated cell cycle
arrest and apoptosis does not occur following DNA damage.
Since the nature of our expression vector relies on the Epstein-Barr virus
nuclear antigen one (EBNA1) for its replication and maintenance, we are
limited to cell lines expressing this protein.  A common method for producing
cell lines from primary B cells is to infect, and thereby immortalise isolated cells
with EBV.  The resulting cell lines, referred to as lymphoblastoid cell lines
(LCLs), have the advantage that, despite the influence of the viral programme,
most cellular systems and the genome remain intact.  For this reason, a panel of
LCLs were tested for their ability to stabilise p53 following exposure to 8 Gy IR.
Cellular p53 levels were compared before and after irradiation (Fig. 16A).  Cell
lines 1.11, 1.26 and 1087 showed little increase in p53 levels following
irradiation and were thus discounted.  Strong inductions were seen in the LCLs
GB.4.C3, 1.25, Kinert and Rosi.  Further tests showed the Rosi cell to be the best
candidate due to the relative ease with which it was possible to produce stable
cell lines.  Unstimulated Rosi cells show little stabilisation of p53:  a slower
migrating band can be seen that is most probably the ubiquitinated form (Fig.
16B).   One hour after irradiation a strong p53 induction can be seen, which is
almost double the intensity at two hours post IR, and then maintained for at
least a further two hours.
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Figure 16. The effect of 8 Gy ionising radiation (IR) on lymphoblastoid cell lines.
(A) Expression of the tumour suppressor p53, 1h following irradiation, in a
panel of different LCLs. (B) Time course of p53 expression in the Rosi cell
line. (C) Tetracycline regulatable expression of stably transfected Pol II
LS*CTD mutants in the Rosi LCL and the effect of 8 Gy IR on the mobility
of the Pol II LS*CTD mutants.
Stable Rosi cell lines of mutants LS*49+50, LS*49+52 and LS*49+NS52
were established.  The expression profile is similar to that seen in Raji:  the Pol
IIb form only appears with mutants LS*49+50 and LS*49+NS52, but not with
the mutant LS*49+52, which contains a wt last repeat (Fig. 16C).  A band can be
seen migrating slightly faster than the IIb form, and is an artefact of  the lysis
procedure resulting from incomplete inhibition of proteases.  It is this band that
is visible with the LS*49+52 mutant, and not IIb.  Comparison of the different
forms present for each mutant reveals a similar pattern to that seen in the Raji
cell lines.  Again, little of LS*49+50 mutant appears to be in the
hyperphosphorylated (IIo) form as compared to LS*49+52, but interestingly this
is not the case for the LS*49+NS52 mutant, that expresses a similar ratio of
forms to that of LS*49+52.  IR exposure causes a shift to the IIo form for all
mutants, probably as a result of increased stress kinase activity (ERK/JNK), and
the transcription of stress-activated genes.  Since c-Abl is activated by IR,
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increased phosphorylation should only be seen in mutants containing a wt last
repeat:  mutants LS*49+50 and LS*49+NS52 should no longer interact and
become phosphorylated by this kinase.  This may explain the small discrepancy
in the amount of the IIo form between mutants LS*49+52 and LS*49+NS52.
2.6 Characterisation of CTD last repeat mutants in the Rosi
LCL
Stable Rosi cell lines were produced for all the mutants.  The same initial
tests were performed as with the previously described cell lines.  Figure 17
shows their expression pattern 24h following induction.  Again, a pattern
similar to that seen in Raji can be seen:  the Pol IIb form is only seen for mutants
LS*49+50, LS49+50ATM and LS*49+NS52.  The shortfall in Pol IIo form
detected results partly from the extraction buffer (RIPA) used, which fails to
extract all nuclear Pol II, and partly that the distribution of the expressed
polymerases is largely cytoplasmic at the time point of extraction (Based on the
time course of distribution of an EGFP-labelled Pol II LS).  It can be seen that
the level of expression is not equal in all cell lines.  This may be due to
incomplete removal of tetracycline in this experiment.
Figure 17. Expression patterns of last CTD repeat mutants in the Rosi LCL.   Cells
were induced to express their respective Pol LS* mutants by removal of
tetracycline. 18 h later, cell extracts were prepared using RIPA buffer, and
mutants visualised following SDS-PAGE/ western blotting using the 3F10
anti-HA antibody.
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Figure 18. The ability of last CTD repeat mutants to induce the hsp70A gene in
response to heat shock.  Rosi cell lines were grown in the presence or
absence of Tc for 24h, after which, α-amanatin [2mg/ml] was added to the
indicated samples and incubated a further 24h.  Cells were exposed to a heat
shock for 2h at 43°C before harvesting of their RNA.  10mg of total RNA
from each sample was probed for levels of hsp70A RNA using a
complementary radioactive probe. The 28S and 18S RNA bands, stained
with ethidium bromide, provide a control for equal loading.
The relative ability of these mutants to transcribe the hsp70A gene was also
assessed (Fig. 18).  In the presence of α-amanatin, only cell lines grown in the
absence of Tc show an induction of the hsp70A gene in response to heat shock,
suggesting all our mutants can functionally replace the endogenous Pol II LS in
the transcription of this gene.  The signal seen for all cell lines is similar to that
of a control cell line, ‘Mock’ which only expresses the endogenous polymerase.
The faint background bands seen for some mutants in the presence of Tc may
result from leakiness in the expression system, or technical error, and are
negligible in comparison to the induction seen.
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2.6.1 Cell viability is not severely affected by removal of the last repeat in
the Rosi cell line
 Analysis of the ability of these mutant polymerases to sustain viability in
the presence of α-amanatin (Fig. 19) contrasts the results seen in Raji (Fig. 13):
all cells show an increased resistance to α-amanatin.  Experiments in Raji
repeatedly show death of the control ’Mock’ cell line around day 7 plus α-
amanatin, whereas death is seen for all cells around day 9 in Rosi.  As in Raji,
the first 7 days are characterised by a major drop in viability for all cell lines.
However, the crisis phase that ensues is more acute in Rosi cell lines, with
almost full viability attained around 25 days, compared to almost 50 days for
Raji cell lines.  Most interestingly, the LS*49+50 mutant does not exhibit a lethal
phenotype in Rosi.  This mutant initially shows a weaker recovery than other
mutants, but is able to restore and sustain viability to over 80%.  This difference
is perhaps inherent to the cell lines:  Raji, alike most BL cell lines, is more
sensitive to stress than LCLs.
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Figure 19. Growth and viability of Rosi cell lines expressing Pol II LS*CTD
mutants in the presence of α-amanatin.  Stably transfected Rosi cells
were induced to express Pol II LS*CTD mutants by removal of tetracycline
(Tc) from their growth medium.  24h after induction, α−amanatin was given
to the medium [2mg/ml]. Viability and cumulative cell growth were
assessed regularly over a period of 26 days.
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2.6.2 Mutation of the final repeat reduces the tyrosine phosphorylation of
Pol II LS in response to IR
If our mutations really affect the tyrosine phosphorylation of CTD by c-
Abl, in response to DNA damage, then the level of phosphorylation on some
mutants should be reduced compared to those containing a wt last repeat.  Cells
expressing the previously untested CKII and 'last repeat' Pol II LS* mutants
were exposed to IR before harvesting one hour later, a time point where the
most tyrosine phosphorylation is to be seen (Baskaran et al., 1993; Baskaran et
al., 1999).  In order to detect the phospho-tyrosine content of the expressed
mutant, immunoprecipitation (IP) is first required to remove the background
signal from other cellular proteins.
Figure 20. Tyrosine phosphorylation of Pol II LS* CTD mutants following IR.
Cells expressing Pol II LS* CTD mutants were irradiated with 12 Gy IR,
then harvested 1h later.  Immunoprecipitation (IP) was performed using the
anti-HA antibody, 3F10.  Samples were separated by SDS-PAGE and
Western blots thereof were stained with either (A) anti-HA (3F10) mAb, to
control IP yield, or (B) the anti-pY antibody, pY100.
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Western analysis of the immunoprecipitates reveals successful IP of the
mutants (Fig. 20A), as visualised using antibody against the HA-tag.  The IIb
form is also immunoprecipitated, since the HA tag is N-terminal.  IIb is only
produced in cells expressing mutants LS*49+50ATM, LS*49+NS52.  A band
migrating slightly faster than IIb can be seen for some mutants, but is a
degradation product other than IIb, which may result from incomplete
inhibition of proteases during IP.
Immunoprecipitated material from irradiated cells was probed with anti-
phospho-tyrosine antibody to determine the tyrosine phosphorylation induced.
The levels of tyrosine phosphorylation detected were overall very weak for all
mutants tested, leading to a low signal/ background ratio.  The blocking
procedures for the anti-HA antibody produced an unacceptable level of
background when used with the anti-phospho-tyrosine antibody, and vice-versa,
thereby preventing stripping and re-probing of the same blots.  Following
testing of several commercially available antibodies, the best results were
obtained using the P-Tyr-100 antibody.  This antibody was raised against a
synthetic peptide, and has been shown to recognise a synthetically
phosphorylated CTD peptide (manufacturer’s claim).  However, it is not clear
how the recognition by this antibody, and other anti-phospho-amino acid
antibodies, is affected by other changes in the surrounding sequence (for
example, phosphorylation of other residues).  Despite the weak signals
obtained, it could be shown that only mutants containing an intact CTD last
repeat become tyrosine-phosphorylated following exposure to IR (Fig. 20B).
Signals could be seen for CKII mutants LS*49+52 -S9A, -S13A, and -S9/13A,
indicating that these mutations do not interfere with c-Abl interaction.
2.7 CKII phosphorylation of the CTD
Through point mutation of the CKII consensus sites in the Pol II LS final
repeat we hoped to destroy this interaction in vivo.  CKII has been shown only
to phosphorylate fragments containing the C-terminal, largely non-consensus
region of CTD, and not N-terminal consensus fragments (Kuenzel et al., 1987).
It is thus still not clear whether the consensus CKII sites are actually real
targets.  Work on the CTD last repeat by the Bensaude group resulted in the
production of rabbit polyclonal antibodies to address this question.  Two
synthetic peptides of the last repeat were produced for immunisation:  one
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phosphorylated on every serine, the other possessing no phosphorylated amino
acids.  The resulting serum was shown in their own tests to specifically
recognise phosphorylated, and non-phosphorylated forms of Pol II LS, however
the CKII consensus sites used could not be determined.  To address this
question, these antibodies were tested for their ability to recognise our last
repeat mutants.  Rosi cells were induced to express the Pol II LS mutants for
24h before addition of α-amanatin for a further 24h, to remove the background
of the endogenous Pol II LS.  Western blots using either polyclonal antibody
against the phosphorylated (DEEP1), or dephosphorylated (DEEN4) peptide
are shown in figure 21A, compared to the loading control using anti-HA
antibody.  The mutants lacking the last repeat (LS*49+50, LS*49+50ATM and
LS*49+NS52) or both CKII sites (LS*49+52 S9/13A), show no response to either
antibody as expected.  However, those containing the final repeat show a mixed
reaction: LS*49M+52 and LS*49+52 react to both antibodies; LS*wtMCS to just
DEEN4.  This result is interesting, since the Bensaude lab failed to identify an in
vivo situation where the DEEN4 antibody recognised the endogenous Pol II LS.
This may be due to a structural artefact of our mutants, or that as a result of
over expression, not all Pol II LS* has been able to become phosphorylated.  The
absence of reactivity to the DEEP1 antibody seen with LS*wtMCS may be
explainable after considering the CKII point mutants:  Pol II LS*49+52 S9A only
reacts with DEEP1, while Pol II LS*49+52 S13A only reacts with DEEN4.  This
suggests that only serine 13 of the last repeat is a CKII target.  The extra seven
amino acids in the LS*wtMCS last repeat may interfere with its structure, or
prevent the interaction with CKII.  Figure 21B shows a summary of the
reactivity of the antibodies which each of the mutants and the epitopes present.
However, it is important to note that these antibodies are polyclonal mixtures
raised against a wt last repeat peptide, and that there reactivity to synthetic
point mutants has not been characterised.  For the purposes of this experiment
we assume structural similarity of the point-mutated sequence to that of wt.
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Figure 21. Phosphorylation specific antibodies determine the level of
phosphorylation at the final repeat CKII sites in vivo.  (A) Expression of
Pol II LS* CTD mutants in stably transfected Rosi cell lines.  Cells were
harvested 48h after induction of expression, and incubation with α-
Amanatin for the last 24h.  Expression levels were determined by staining
Western blots with the high-affinity anti-HA antibody 3F10.  Polyclonal
antibodies raised against a repeat 52 peptide, phosphorylated at positions 5,
9 and 13 (DEEP), were used to determine the level of phosphorylation
resulting from CKII activity. Polyclonal antibodies raised against an
equivalent, non-phosphorylated peptide (DEEN), were used as a control. (B)
The table reflects the potential CKII target epitopes present in each CTD
mutant, and their recognition by the phosphorylation-specific antibodies.
2.  Results 57
2.8 Analysis of differences in gene expression between
mutants
Unlike Raji, the Rosi cell line appears to have an intact p53 and ATM
response.  This can be seen at the level of transcription by the up regulation and
down regulation of individual gene transcription at various time points
following stimulus.  Nuclear run-on analysis of Rosi cells one hour following
exposure to 12 Gy IR reveals the up-regulation of known p53 targets, in
accordance with data already published (Zhao et al., 2000).
Figure 22. The effect of ionising radiation on active gene transcription in Rosi cells
expressing a Pol II LS* mutant.  Expression of the LS*49+52 mutant was
induced for 24h before the addition of 2mg/ml  α-amanatin.  Following a
further 24h incubation, a portion of cells were exposed to 8 Gy IR and
nuclei harvested 1h later.  For each treatment, the labelled RNA from 2x107
nuclei was hybridised to an Atlas human cancer 1.2 array (CLONTECH).
Identical fields from arrays hybridised with either RNA from irradiated cells
(+IR) or that of non-irradiated cells (-IR) are compared. p53 target genes
induced following IR are labelled.
Comparison of active transcription by two mutants lacking the CTD last
repeat (LS*49+50; LS*49+NS52) to that of a mutant where it is present, reveals
no reproducible difference in the specific transcription of genes (data not
shown).  Run-on analysis of active transcription 1 hour post-IR reveals the
induction of genes known to be induced by p53 in response to IR (Fig. 22). The
cyclin-dependent kinase inhibitor, p21/Waf1/Cip1 is strongly induced, as is the
proliferating cell nuclear antigen gene (PCNA).  The gene for the Fas/APO-
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1/CD95 membrane receptor, the cell cycle regulator GADD45, and the
angiogenesis regulator thrombospondin were also significantly up-regulated.
This type of array is designed as an initial screen for gene targets and is not
designed for accurate quantification, thus the changes in gene expression noted
here are purely qualitative (For quantification of gene expression in response to
IR see (Zhao et al., 2000).
Comparison of mutants revealed no reproducible difference in the level of
transcription of single gene (Fig. 23).  The only notable difference between
mutants is the overall, slightly weakened signal for all genes transcribed by the
LS*49+50 mutant, as also previously seen for the same mutant in the Raji cell
line (Fig. 4).  A control region at the base of each array allows the comparison of
specific gene expression with that of 'house-keeping' genes, three genomic DNA
probes (Positions 2,18, and 34), and a fragment of the vector pUC19 (Position
36).  The episomal vectors contained in these cell lines also contain fragments of
pUC19, that are transcribed by both RNA polymerase II, and III due to the
presence of their respective promoters within the vector backbone.  Since these
activities are not inhibited by α-amanatin, and are constant between cell lines,
this spot serves to control that RNA from approximately the same number of
nuclei is being compared.  At least 5 probes on the Atlas 1.2 array contain Alu-
sequence elements and thus have cross reactivity with RNA Pol III transcripts,
leading to their increased intensity.
(overleaf)
Figure 23. Run-on analysis of polymerase density on 1176 genes.  The Pol II
mutants LS*49+50, LS*49+52 and LS*49+NS52 were induced for 24h
before the addition of 2mg/ml α-amanatin.  Following a further 24h
incubation, cells were exposed to 8 Gy IR and nuclei harvested 1h later.  For
each cell line, the labelled RNA from 2x107 nuclei was hybridised to an
Atlas  human 1.2 array (CLONTECH).
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3.0 Discussion
The aim of this project was to examine the function of the final repeat of
the RNA polymerase II large subunit CTD.  The CTD has been shown to be
essential at almost every stage of in vivo transcription:  initiation, elongation,
termination and pre-mRNA processing.  The CTDs of different organisms vary
in the number of repeats of a consensus sequence YSPTSPS.  In mammals, the
number of repeats is 52, however, not all repeats conform to the consensus
sequence.  It has long been postulated that such ´non-consensus´ repeats may
have evolved to fulfil more specific functions.  The majority of work to examine
this hypothesis has relied on reconstituted, in vitro transcription systems or
transiently transfected reporter constructs.  Additionally, synthesised
polypeptides representing consensus-, and non-consensus repeats have been
used to assess their ability to catalyse the different stages of pre-mRNA
processing (Fong and Bentley, 2001).  Although valid, these techniques fail to
account for the effects of chromatin and the controlled recruitment of factors to
transcription complexes.  The last repeat of the Pol II LS CTD is the site of
interaction for two kinases known to play roles in the response to DNA
damage; a response that due to the number of unknown parameters, would be
difficult to reproduce in vitro.  For this reason a system was used that allowed
the study of Pol II LS CTD mutants in vivo.  This system requires that all
mutants be based on a Pol II coding sequence containing a point mutation that
confers resistance to the RNA polymerase inhibitor, α-amanatin.  The
endogenous polymerase is effectively, chemically ´knocked-out´ when cells are
grown in the presence of α-amanatin, enabling the ability of the mutants to
replace the function of the endogenous polymerase to be examined.
The α-amanatin system:
The toxin produced by the ‘death cap’ mushroom (Amanita
phalloides), α-amanatin, is a cyclic peptide that binds with high affinity to the
Pol II LS.  Binding of α-amanatin to the elongating Pol II complex reduces the
rate of translocation from several thousand to only a few nucleotides per
minute (Chafin et al., 1995; Rudd and Luse, 1996).  Binding of α-amanatin still
permits the formation of the phosphodiester bond between ribonucleotides, but
inhibits the following translocation step, and therefore elongation (de
3.  Discussion 61
Mercoyrol et al., 1989; Vaisius and Wieland, 1982).  The efficacy of this
inhibition in cell culture experiments appears dependent on the permeability of
the cell to α-amanatin:  an incubation time of 24h is required for complete
inhibition of the endogenous Pol II in cultured Raji cells (Meininghaus et al.,
2000), whereas inhibition occurs in minutes following treatment of isolated
nuclei with the same concentration.
Structural analysis has revealed that the site of α-amanatin binding lies
beneath the ´bridge helix´, which extends across the cleft between the two
largest Pol II subunits, Rpb1 and Rpb2, within a ´funnel´-shaped cavity in the
Pol II structure (Bushnell et al., 2002).  A number of different point mutations
conferring α-amanatin resistance have been described, most mapping to this
site, which lies in the region ´F´ of the Pol II large subunit (M. musculus,
(Bartolomei and Corden, 1987); R. rattus, (Crerar et al., 1983); D. melanogaster,
(Chen et al., 1993); C. elegans, (Rogalski et al., 1990).  The α-amanatin resistant
Pol II mutant C4 from D. melanogaster exhibits a reduced elongations rate in
vitro (Coulter and Greenleaf, 1985), and mutations in the same region of the Pol
III large subunit also affect elongation (Thuillier et al., 1996; Thuillier et al.,
1995), suggesting the region where α-amanatin binds is involved in
transcription elongation.  These findings are consistent with the finding that the
α-amanatin binding site is too far from the active site to interfere with
nucleotide entry or RNA synthesis (Bushnell et al., 2002).
The resulting block in Pol II elongation caused by α-amanatin creates a
problem for the cell in that it creates a physical block on the gene that it was
transcribing.  It is therefore not surprising that treatment of cells with α-
amanatin induces the degradation of the Pol II LS (Nguyen et al., 1996).
Treatment of cells with agents that cause DNA lesions (e.g. UV radiation or
cisplatin) also results in a transcription block, and degradation of Pol II LS.  In
both cases degradation occurs through the ubiquitin proteasome pathway
(Ratner et al., 1998).  The E3 ubiquitin-protein ligase, Rsp5, is the most likely
candidate for this activity.  Rsp5 has been shown to interact with the CTD of Pol
II via its WW domain (Chang and Kornberg, 2000), and mediates the
ubiquitination of lysines in the Pol II LS, non-CTD region (Ratner et al., 1998).
That Rsp5 interacts directly with the CTD suggests that a modification of the
CTD in response to the stalling of a polymerase could control its recruitment to
the Pol II complex (Chang et al., 2000).  Treatment of cells with the
transcriptional and CTD kinase inhibitor 5,6-dichloro-1-β-D-
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ribofuranosylbenzimidazole (DRB) blocks the ubiquitination and degradation
of Pol II LS following UV treatment, implicating one of these kinases in the
control of this response (Luo et al., 2001).
3.1 Removal of the last CTD repeat induces the degradation of Pol
II LS to the IIb form
In order to study the role of the last repeat in transcription, various α-
amanatin resistant mutants were produced, and expression vectors thereof
stably introduced in to several cell lines.  Expression of the Pol II LS mutants is
controlled through a tetracycline-inducible system:  in the presence of
tetracycline, expression is inhibited (Tc-off).  Following the establishment of
stable cell lines, the effectiveness of this system to regulate expression was
controlled.  In the absence of Tc, expression of the Pol II LS mutants could be
observed. All the mutants produced (with the exception of Pol II EGFP) exhibit
a similar expression profile to that of the endogenous mammalian Pol II LS,
which typically migrates with a weight of between approximately 214-240 kDa
relative to the degree to which it is phosphorylated (Corden et al., 1985).
However, an additional form of Pol II LS was seen to appear in mutants where
the last repeat is absent, or severely disrupted.  This form migrates faster than
the other forms, IIa and IIo, and with a rate suggestive of a molecular weight of
approximately 180 kDa.  In Raji cells, a decrease in the amount of polymerase in
the IIo form occurs concomitant with the appearance of this form, suggesting a
conversion of one form to the other.  These observations are characteristics of
the IIb form of RNA polymerase II (Chambon et al., 1972).
The IIB form was originally described as one of three subspecies of RNA
polymerase II:  IIO, IIA and IIB (Kedinger and Chambon, 1972; Schwartz et al.,
1974).   These forms differ in their ability to be phosphorylated (Dahmus, 1981),
and in the apparent molecular weight of their largest subunit, designated IIo
(240 kDa), IIa (214 kDa) and IIb (180 kDa), for forms IIO, IIA and IIB,
respectively (Dezelee et al., 1976; Roeder et al., 1976).  The IIo and IIa forms are
identical in sequence, but differ from each other by the degree to which they are
phosphorylated.  Pol IIo arises from the phosphorylation of multiple sites
within the CTD of Pol IIa (Cadena and Dahmus, 1987; Kim and Dahmus, 1988),
and the Pol IIb form results from the proteolytic cleavage of the CTD by an
unknown protease (Allison et al., 1988; Corden et al., 1985).
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Work by Dahmus and colleagues has extensively characterised these
forms, and revealed the importance of the CTD in the regulation of
transcription (reviewed in Dahmus, 1996).  The discovery that the transition
from initiation to elongation phases occurs concomitant with the conversion of
Pol IIa to the IIo form  (Payne et al., 1989) not only supported other groups’
data identifying IIo as the transcriptionally active form (Bartholomew et al.,
1986; Cadena and Dahmus, 1987), but also led to the dismissal of Pol IIb being a
relevant form in vivo.  With improved resources for the preparation of samples,
notably the use of protease inhibitors, the Pol IIb form was rarely further seen
to any extent in tissue extracts of proteins (Kim and Dahmus, 1986; Payne et al.,
1989).  After this point, no further research was performed on the IIb form, since
it appeared to be an artefact found only in vitro.  The in vivo proteolytic
degradation of mutants lacking the last CTD repeat, to the IIb form, suggests
this may now not be the case.  An examination of earlier work may therefore
assist our understanding of the properties of this form.
Initial comparisons of the abilities of the three, purified Pol II subspecies
to transcribe the major late promoter of adenovirus-2 revealed that only the IIA
and IIO forms are capable of selective transcription in vitro.  However, all three
forms were able to transcribe calf thymus DNA, which is known to contain
nicks, and thus permits non-selective transcription (Dahmus and Kedinger,
1983).  In these experiments, monoclonal antibody raised against the CTD was
able to block selective transcription from several promoters, but had no effect
on non-selective transcription.  These findings are consistent with the
requirement of the CTD for transcription initiation in vivo.  Later, work by the
same group using a polymerase-dependent transcription system, reconstituted
from partially purified transcription factors, demonstrated that actually all
three forms could transcribe the major late promoter of adenovirus-2 (Kim and
Dahmus, 1989).  However, this work suggests that the IIA and IIB forms are
transcriptionally more active than IIO – a finding not supported by current
research.  One of the major problems of reconstituted systems is knowing what
factors need to be present, and the physiological concentrations at which they
are should be present; reactions may occur in vitro, which would otherwise not
in vivo and vice-versa.  In another study, a mutant of the Pol II large subunit was
produced, possessing just five CTD repeats.  This mutant is able to initiate
selective transcription in vitro, and on a transiently-transfected template in vivo,
but is unable to transcribe a chromatin template (Meininghaus et al., 2000;
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Meininghaus and Eick, 1999).  Comparison of the same truncated mutant with
the Pol IIb form produced by ´last repeat´ mutants revealed that they are of
approximately the same size.  Based on these findings, it is unlikely that the Pol
IIB form is active in in vivo transcription.
3.2 Removal of the last CTD repeat affects the viability and
proliferation of the Raji Burkitt’s lymphoma cell line
It is possible that the ability of α-amanatin to inhibit RNA Pol II
elongation takes advantage of an as yet, undiscovered, endogenous mechanism
for transcriptional regulation.  Some studies of α-amanatin resistant RNA Pol II
large subunits suggest that these polymerases may not behave exactly as the
endogenous Pol II large subunit:  Pol II large subunits with a reduced affinity
for α-amanatin have been shown to confer developmental defects in D.
melanogaster (Chen et al., 1993), induce pleiotropic effects during the
differentiation of rat myoblasts (Crerar et al., 1983), and may demonstrate a
reduced elongation rate compared to wild type polymerase (Coulter and
Greenleaf, 1985).  Such defects have not yet been described for the α-amanatin
resistant Pol II LS used in this work, which has already been shown to
successfully replace the function of the endogenous Pol II LS in vivo
(Meininghaus et al., 2000).
 Cell lines expressing Pol II LS* CTD mutants were tested for their
ability to grow in the presence of α-amanatin.  Expression of an α-amanatin
resistant, wild type Pol II LS (LS*wtMCS), or a mutant thereof containing the
last repeat (LS*49+52), transferred α-amanatin resistance to the cell line.  Cells
continue to proliferate during the first nine days post-α-amanatin, before
entering a ‘crisis phase’ of reduced proliferation lasting between 20 and 30
days.  The inhibition of transcription through α-amanatin appears to induce the
stabilisation of cellular mRNA by an as yet, unknown mechanism (Kuo et al.,
1995; Meininghaus et al., 2000; Yamaizumi and Sugano, 1994).  This may
explain the continued exponential growth seen in the first few days post-α-
amanatin.  Cellular stress due to the over- or under-expression of the exogenous
polymerase, or titration of transcription factors by the Tc-transactivator (TcTA)
and Pol II LS* itself, may lead to sub-optimal gene expression.  Although the life
span of stabilised mRNAs is not known, it is tempting to speculate that the
3.  Discussion 65
crisis phase results from a shortage of essential mRNAs.  During this period,
where little cumulative growth is observed, the cells are effectively selected for
those adapted to their new conditions.  In contrast, a control cell line expressing
no polymerase (LS*mock), or an α-amanatin resistant mutant possessing just 5
CTD repeats (LS*∆5), exhibit no resistance to α-amanatin.  Presumably, these
cells undergo apoptosis, as is described for another transformed cell line
(HELA) following α-amanatin treatment (Koumenis and Giaccia, 1997).
Another control mutant tested contains a CTD truncated to 31 repeats (LS*∆31)
(Meininghaus et al., 2000).  This mutant supports growth and viability for the
first nine days, alike all the other mutants tested.  However, this mutant fails to
recover from the crisis phase encountered thereafter, indicating that this mutant
can fulfil some, but not all the functions of the endogenous polymerase.
Interestingly, a mutant lacking the last repeat (LS*49+50) exhibits a phenotype
similar to LS*∆31, whereas a mutant of equivalent repeat number
(RajiLS*49+52) can sustain viability and proliferation.  This is a surprising
result, since a genetically modified mouse possessing a polymerase with just 39
repeats is viable (Litingtung et al., 1999).  It should be noted, however, that the
mutant used in that work, alike the majority of existing CTD deletion mutants,
still contained the last CTD repeat.  The repetitive nature of the CTD sequence
creates problems for its genetic manipulation.  Most mutants of differing CTD
length characterised in detail to date were invariably produced by internal
deletion, and thus retain the last repeat.  No reproducible difference was seen
between the CKII point-mutants produced, suggesting that the phosphorylation
of the last repeat by CKII does not affect growth and proliferation.  It is also
interesting to note that a mutant containing a fusion of the CTD to the
enhanced, green fluorescent protein (LS*wtEGFP) behaves no differently than a
wild type mutant, despite EGFP potentially blocking access of other factors to
the last repeat, or interfering with the CTD itself.
3.3 Removal of the last CTD repeat only slightly affects the
viability and proliferation of the Rosi LCL
Repetition of the growth and survival assay in a different cell line, Rosi – a
lymphoblastoid cell line, did not produce the same result as in Raji – a Burkitt’s
lymphoma cell line.  In the Rosi cell line, the LS*49+50 mutant is able to sustain
3.  Discussion 66
growth and viability in the presence of α-amanatin.  This mutant exhibits a
weaker recovery compared to other mutants, but still survives α-amanatin
selection.  What could explain this difference?  Since the cell lines are
polyclonal, and the expression vectors do not integrate, this difference is
unlikely to be a result of an inferior clone, rather the cell lines instead.
A notable difference between mutants expressed in the Rosi LCL and
the various BL cell lines was the relative proportions of the Pol IIb form to that
of IIa and IIo.  It was the general impression during this work that less IIb form
was generated in the Rosi LCL than in the BL cell lines tested. An increased
degradation of Pol II LS to its likely, inactive IIb form, may account for the
overall global reduction in transcription seen, and loss of viability in BL cell
lines.
Burkitt’s lymphoma cells are very sensitive to sub-optimal growth
conditions and undergo apoptosis induced by oxidative stress when seeded at
low cell density (Brielmeier et al., 1998; Falk et al., 1993).  LCLs on the other
hand are comparatively robust (Bornkamm GW, personal communication).
Both the Raji BL and Rosi LCL are infected with Epstein-Barr virus (EBV),
which remains latent under normal tissue culture conditions.  The Rosi LCL is
dependent on the EBV programme for its immortality, whereas the Raji BL
(Pulvertaft, 1964) contains a t(8;14) chromosomal translocation, placing the c-
myc gene under the control of the immunoglobulin enhancer, leading to its
uncontrolled expression (Spencer and Groudine, 1991).
 In EBV-immortalised cells, only a limited number of EBV genes are
expressed, including those required for episome maintenance (EBNA1),
proliferation (EBNA2) and survival (LMP1).  EBNA2 is a viral transactivator
which activates gene expression, including that of c-myc, through its interaction
with the transcription factors RBPjK and PU.1 (Reviewed in Bornkamm and
Hammerschmidt, 2001). Paradoxically, c-Myc over expression has the effect of
reducing the expression of these viral genes (Staege et al., 2002), perhaps
explaining why BL cells are more susceptible to apoptosis.  The ability of the
LS*49+50 mutant to confer α-amanatin resistance might therefore depend on
the sensitivity of a cell line to oxidative stress.
Interestingly, both c-Abl and c-Arg are activated following oxidative
stress, and induce apoptosis (Cao et al., 2001; Sun et al., 2000).  The activity of
both nuclear and cytoplasmic c-Abl is inhibited through binding of the pag gene
product, PAG (also known as macrophage 23-kD stress protein:  MSP23), to its
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regulatory SH3 domain.  Oxidation of PAG may remove its inhibitory effect,
leading to increased Abl activity.  The pag gene is constitutively expressed in
most human tissues, but its expression is increased in tissues with a high rate of
proliferation, or in response to oxidative stress (Prosperi et al., 1998).  It is
possible that phosphorylation of RNA Pol II by c-Abl confers protection against
oxidative stress.
3.4 Removal of the last CTD repeat does not affect the specific
transcription of genes.
The removal of the Abl-Pol II interaction may be expected to affect the
transcription of some genes.  Indeed, c-Abl has been shown to influence
transcriptional elongation at the HIV-1 promoter (Baskaran et al., 1999).
However, analysis of active transcription by Pol II mutants containing or
lacking the last CTD repeat revealed no specific alteration in the transcription of
1176 genes.  The only notable difference seen was a general weaker signal for all
class II genes transcribed by a mutant lacking this region.  Since the last CTD
repeat is target for kinases involved in the response to DNA damage it has been
postulated that this repeat may be important for their signalling to the
transcription machinery (Baskaran et al., 1999; Bregman et al., 2000;
Oelgeschlager, 2002).  The c-Abl kinase is activated following DNA damage
by the ATM kinase (Baskaran et al., 1997b).  ATM is activated by a specific
type of DNA damage caused by chemical agents such as cisplatin, or ionising
radiation (IR) that induce DNA double-strand breaks (Durocher and Jackson,
2001).  Both the activation of c-Abl and stabilisation of p53 occur within one
hour of such an insult.  IR induced tyrosine phosphorylation of the RNA Pol II
CTD is maximal at this time point (Baskaran et al., 1993).
Since both c-Abl and p53 could affect the activation of gene transcription,
stable cell lines with intact ATM signalling were compared on a wt (Rosi) or
mutant (Raji) p53 background.  This enables the transcriptional effects of c-Abl
to be distinguished from those of p53.  In the presence of α-amanatin, CTD
tyrosine phosphorylation was only seen in mutants containing the CTD last
repeat, following irradiation.  In Raji cells, no effect on active gene transcription
was seen at this time point following IR exposure.  This is an important finding,
since it would suggest that contrary to speculation, activation of c-Abl alone
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does not noticeably affect transcription elongation.  Reproduction of the same
experiment in Rosi cells revealed the induction of genes known to be induced
by p53 following IR (Zhao et al., 2000).  However, no difference in the
induction of these genes could be seen between mutants containing or lacking
the last CTD repeat.  This suggests that tyrosine phosphorylation of the Pol II
CTD by c-Abl neither directly or indirectly influences transcription elongation.
So far, only signalling to the Pol II CTD has been discussed, however, it is
also possible that, as in the response to transcription blockage, Pol II itself
induces the response to DNA damage (Ratner et al., 1998).  It is thus possible
that the last CTD repeat not only participates in signal transduction to Pol II,
but also away from it.  These data suggest that the last CTD repeat, and
therefore its interacting partners c-Abl and CKII, are not important for the
induction of the DNA damage response.
3.5 Mutation of the last CTD repeat CKII sites does not
specifically affect the stability, or transcriptional ability of
Pol II LS.
In the functional tests performed in this study, the Pol II LS*CTD mutants
containing point mutations in either one (S9A; S13A), or two (S9/13A) of the
potential CKII sites in the last repeat failed to behave differently from non-
mutated controls.  This suggests that these sites are not essential for the
function of Pol II in the cell lines used.  The Pol IIb form was induced by
mutants lacking the last CTD repeat, but not by mutants containing point-
mutated CKII sites, indicating that phosphorylation at these sites does not affect
Pol II LS stability.  However, these data were produced in tissue culture, and
cannot discount that this phosphorylation serves an important function in vivo.
3.6 Only one CKII site within the last repeat is phosphorylated
in vivo
Work performed in co-operation with the group of Bensaude failed to find
a circumstance when CKII does not phosphorylate the last CTD repeat.
Polyclonal antibodies produced for that study were raised against
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phosphorylated (DEEP1), or non-phosphorylated (DEEN4) last CTD repeat.
Analysis of CKII point mutants with these same antibodies revealed more
specific information about the CKII phosphorylation of the last repeat.  Only
mutants containing Ser13 were recognised by the DEEP1 antibodies, and those
lacking Ser13 were recognised by DEEN4, suggesting this to be the only site of
CKII phosphorylation.  Some wt mutants exhibited reactivity to both antibodies,
but this may be an artefact of over expression, since the wt, endogenous Pol II
LS reacts only with DEEP1.  CKII phosphorylates serines and threonines
immersed in acidic sequences within proteins and peptides.  The minimum
requirements for phosphorylation are depicted by the sequence S/T XX D/E,
where X is any non-basic amino acid (Reviewed in (Allende and Allende,
1995)).  In naturally occurring CKII substrates, the phosphorylated threonine or
serine is surrounded by a cluster of acidic residues.  This might explain why
Ser13 is preferentially phosphorylated compared to Ser9.
3.7 The role of the last CTD repeat in the processing of mRNA
and the response to DNA damage
The specific phosphorylation of the CTD regulates Pol II initiation and
elongation in vivo through the orchestrated recruitment and displacement of
positive and negative elongation factors (Majello and Napolitano, 2001).  How
these processes are regulated may partly be explained in that the CTD kinases
discovered so far, exhibit preferences for the different amino acids present in
the consensus repeat YSPTSPS.  This suggests a mechanism by which the
pattern of phosphorylation may be altered to create or destroy sites of protein-
protein interaction.  In addition, the presence of non-consensus repeats
provides for further specificity, enabling factors to be recruited to specific
regions of the CTD.  Work by the group of Bentley suggests that this may
indeed be the case, showing that consensus and non-consensus regions of the
mammalian CTD possess different properties for the processing of pre-mRNA.
The first 27 repeats of the CTD conform largely to the consensus sequence and
support 5’ capping, whereas the non-consensus repeats 27-52 support 5’-
capping, splicing and 3’ processing of RNA (Fong and Bentley, 2001).
The majority of CTD kinases target serine residues (for review see Kobor
and Greenblatt, 2002).  The change from phosphorylation at serine-5 of the CTD
consensus repeat at promoter proximal regions, to serine-2 during elongation
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and termination, has been shown to correlate with the change in composition,
and activity of complexes present in these regions (Komarnitsky et al., 2000).
The activity of the capping enzyme complex is dependent on serine-5
phosphorylation (Rodriguez et al., 2000; Schroeder et al., 2000), whereas the
recruitment and activation of splicing factors requires serine-2 phosphorylation
(Licatalosi et al., 2002).  Based upon these observations, many laboratories have
performed screens for proteins recognising different phosphorylated forms of
CTD, the outcome of which being the identification of novel and known factors
implicated in elongation, repression and pre-mRNA processing (reviewed in
(Howe, 2002)).  It is therefore possible that the phosphorylation of the last
repeat by CKII, or the phosphorylation of CTD tyrosines by c-Abl and c-Arg
regulates the recruitment to Pol II, of factors involved in pre-mRNA processing,
or the DNA damage response.
Tyrosine-1 of the CTD is the only residue to be completely conserved
between all repeats, and has been shown to be essential for viability in yeast
(West and Corden, 1995).  The phosphorylation of this residue may therefore be
expected to affect some function of the CTD, and has been shown to overcome
the requirement of Tat for the activation of the HIV promoter (Baskaran et al.,
1999).  However, in the experiments performed during the course of this work,
no effect on the transcription of any specific genes has been seen using mutants
no longer able to interact with the only currently described CTD tyrosine
kinases.  A role for tyrosine-1 phosphorylation in the regulation of pre-mRNA
processing can not be ruled out:  by recruiting specific splicing and 3’processing
factors to the CTD, the preferential production of certain splice variants could
be achieved in response to cellular stress.  Alternatively, tyrosine-1
phosphorylation may control the presence of factors that target the degradation
of the polymerase.  We have shown here that mutants no longer able to interact
with the only known CTD tyrosine kinases appear sensitive to degradation to
the Pol IIB form.  Elongation blocks caused by DNA lesions have been shown to
target the destruction of RNA Pol II through the recruitment of the Rsp5
ubiquitin ligase to the CTD (Beaudenon et al., 1999; Huibregtse et al., 1997).
Tyrosine phosphorylation of the CTD may thus play a role in regulating the
stability of the Pol II large subunit, perhaps through the negative regulation of
factors that target its digestion.  However, this theory is not convincing, given
that inhibitors of c-Abl and c-Arg tyrosine kinases fail to induce the Pol IIb
form.
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3.8 Outlook
The orchestration of transcriptional-, and co-transcriptional processes
through phosphorylation of the Pol II CTD was undoubtedly an evolutionary
development of major significance in higher eucaryotes.  It can therefore be
assumed, that pathways resulting in the modification of this domain have some
influence on these processes.  During this work I tried to identify genes that
depend on signalling through the last repeat of Pol II LS for their regulation
(activation of transcription).  Despite much literature suggestive of the opposite,
this does not appear to be the case.  However, this does not exclude the
possibility that signalling through the last repeat may regulate gene
transcription in another way, for example, through pre-mRNA processing.
Some preliminary tests were performed during the course of this work, but to
little avail.  Since the potential effects could be gene specific, the problem arises
of knowing which genes are affected:  using the chromatin IP (ChIP) technique
in combination with a DNA array composed of many different promoter
regions, it may be possible to identify promoters to which the c-Abl and CKII
kinases are recruited.
The major finding of this work was the discovery that in vivo expression
of a mutant lacking the last CTD repeat, resulted in the appearance of the Pol
IIb form.  This is the first time the Pol IIb form has been identified in vivo, and
suggests that the last CTD repeat may regulate its formation.  Since the Pol IIb
form is probably inactive, degradation to this form may provide a novel
mechanism for transcriptional control.  Initial experiments to identify the
protease responsible, or agents that induce its activation have proved
unsuccessful.  Further experiments are required to identify this protease, and
other interacting partners of the last CTD repeat.
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4. Materials
4.1 Suppliers
4.1.1 Chemical reagents
α-amanatin Roche Diagnostics, GmbH, Mannheim
Acrylamide Carl Roth GmbH & Co., Karlsruhe
Agarose Invitrogen GmbH, Karlsruhe
Bacto-agar Difco Laboratories, Michigan, USA
Bacto-yeast extract “
Bacto-tryptone “
DNA ladders Promega Corp., Wisconsin, USA
dNTPs “
Foetal calf serum Biochrom KG, Berlin
L-glutamine Invitrogen GmbH, Karlsruhe
Neomycin/G418 Promega Corp., Wisconsin, USA
NTPS Roche Diagnostics, GmbH, Mannheim
Penicillin-streptomycin Invitrogen GmbH, Karlsruhe
Protein molecular weight markers Bio-Rad laboratoriesGmbH, München
RMPI-1640 medium Invitrogen GmbH, Karlsruhe
Sephadex-G50, DNA grade Amersham Pharmacia Biotech, Freiburg
4.1.2 Radioactive Isotopes
Radioactively labelled reagents were used before the expiration of their first
half-life.
[α-32P] dCTP (3000Ci/mmol, 10mCi/ml) Amersham Pharmacia Biotech, Freiburg
[α-32P] dCTP (800Ci/mmol, 10mCi/ml) “
4.1.3 Enzymes
Alkaline phosphatase Promega Corp., Wisconsin, USA
DNAse I, RNAse-free (10U/µl) Roche Diagnostics, GmbH, Mannheim
Klenow fragment (1U/µl) Promega Corp., Wisconsin, USA
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Proteinase K  (20U/µl) Promega Corp., Wisconsin, USA
Pfu DNA polymerase “
Restriction endonucleases Promega Corp., Wisconsin, USA
RNAse A (50U/µl) Roche Diagnostics, GmbH, Mannheim
RED-Taq DNA polymerase Sigma-Aldrich GmbH, Deisenhofen
T4-polynucleotide kinase (10U/µl) Promega Corp., Wisconsin, USA
T4-DNA ligase (400U/µl) “
4.1.4 Antibodies
Primary antibodies:
3F10:
A rat monoclonal antibody raised against an epitope contained in the
haemagglutinin polypeptide of the human influenza virus (Roche Diagnostics,
GmbH, Mannheim)
DEEN4:
A rabbit polyclonal antibody raised against the peptide TSPAISPDDSDEEN. (A
gift from Olivier Bensaude, Paris, France)
DEEP1:
A rabbit polyclonal antibody raised against the peptide TS-PPAIS-PPDDS-
PDEEN. (A gift from Olivier Bensaude, Paris, France)
Pol 3/3:
A mouse monoclonal antibody that recognises an evolutionary-conserved
epitope in the Pol II large subunit (non-CTD region).  Originally produced by E.K.
Bautz, University of Heidelberg.  Received as a gift from Olivier Bensaude, Paris,
France
PY-100:
A monoclonal antibody (IgG1) derived from mice immunised with a synthetic
phospho-tyrosine peptide. NEB/Cell Signalling Technology, Frankfurt am Main
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2C8:
A mouse monoclonal antibody (IgG1) raised against a synthetic phospho-
tyrosine peptide. Nanotools, Teningen
Secondary antibodies:
Goat anti-rat HRP conjugate: Santa Cruz Biotech, California, USA
Anti-mouse HRP conjugate Promega Corp., Wisconsin, USA
4.1.5 Disposables and Kits
3MM-paper Whatman Ltd., Kentucky, USA
Agar plates Greiner GmbH, Frickenhausen
Atlas Human 1.2 cDNA Arrays CLONTECH,
Cell culture plasticware Greiner GmbH, Frickenhausen
General laboratoryware GLW GmbH, Würzburg
DNA Midi/Maxi kits Qiagen GmbH, Hilden
ECL™ kit AmershamPharmacia Biotech, Freiburg
Electroporation cuvettes, 2mm, 4mm Peqlab, Erlangen
Hybond N+ nylon membrane AmershamPharmacia Biotech, Freiburg
Immobilion P, PVDF membrane Millipore GmbH, Eschborn
Oligonucleotides Metabion GnbH, München
Parafilm Dynatech, Denkendorf
Polypropylene tubes 15 ml, 50 ml Beckton-Dickinson GmbH, Heidelberg
Reaction viles 1.5 ml, 2 ml Eppendorf-Netheler-Hinz, Hamburg
Rediprime DNA labelling kit AmershamPharmacia Biotech, Freiburg
Sterile filters 0.22 µm, 0.45 µm Millipore GmbH, Eschborn
Tri-fast RNA extraction kit Peqlab, Erlangen
X-ray film (XAR5, BIOMAX-MS) Eastman Kodak Co, New York, USA
4.1.6 Laboratory equipment
-80°C  freezer Colora Messtechnik GmbH, Lorch
Oven Heraeus Sepatech GmbH, Osterode
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Bacteria incubator Heraeus Sepatech GmbH, Osterode
Bacteria shaker (Series 25) New Brunswick ScientificCo., NJ, USA
Centrifuge, Sepatech Varifuge 3.2 RS Hereaus Sepatech GmbH, Osterode
Centrifuge, Sigma 2K15 Sigma Centrifuges GmbH, Taufkirchen
Centrifuge, Sorval RC5C and rotors GS3, DuPont GmbH, Bad Homburg
HS4, and SS34
DNA thermal cycler Therma-Hybaid GmbH
Electroporator (eucaryotic cells) Bio-Rad laboratories GmbH, München
Electroporator (bacteria) Peqlab, Erlangen
Flow hood work bench Bio-Flow technik, Meckenheim
Fuchs-Rosenthal cell chamber GLW GmbH, Würzburg
Gammacell 40 Atomic Energy of Canada L.t.d.
Gel electrophoresis units (nucleic acids) Bio-Rad laboratories GmbH, München
Gel electrophoresis (protein), TE22 AmershamPharmacia Biotech, Freiburg
‘Mighty Small’ series
Hybridisations oven, MKII MWG Biotech GmbH, Ebersberg
Light microscope, Axiovert 135 Carl Zeiss Jena GmbH, Göttingen
Mammalian cell incubator, Hereaus Sepatech GmbH, Osterode
Hereaus-6000
pH-meter, Multi-Calimatic 763 Knick
Radioisotope counter QC-4000 Bioscan Inc., Washington D.C., USA
Speed-vac, concentrator SVC100 Savant Instruments Inc., NY, USA
Spectrophotometer DU-64 Beckman Instruments GmbH, München
Thermomixer 5436 Eppendorf-Netheler-Hinz, Hamburg
Transformer (power pac 300) Bio-Rad Laboratories GmbH, München
UV transilluminator TL-33 UVP Inc., Calafornia, USA
Vortexer, Vortex Genie 2 Bender & Hobein GmbH, Ismaning
Water purification system Millipore GmbH, Eschborn
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4.2 Materials for cloning
4.2.1 Oligonucleotides
All sequences are listed with the standard 5’-3’ orientation.  All
oligonucleotides were manufactured by Metabion GmbH, Martinsried
Primers for MM128-MCS:
wt‡
5’CTCCTGCTGACGCACCTGTTCT 3’
d31fl
5’GTCCCCAAACTCACCCTGAA 3’
RDC17-2
5’GACCGGTTTAAACGCGGCCGCTGAGCGAACAGGGCGAAGAGCTGG3’
RDC17-3
5’CGCCCTGTTCGCTCAGCGGCCGCGTTTAAACCGGTCGTTCTCCTC3’
Primers for RDC135wt (LS*wtEGFP):
EGFP Fwd.:
5’AACGACCGGTTTGTGAGCAAGGGCGAGGAGCTGTTCACC 3’
EGFP Rev.:
5’AAAAGGAAAGCGGCCGCGTCACTTGTACAGCTCGTCCATGCCGAG3’
RX2 primers:
RX2 49+50 Fwd.:
5’CAAGGGCTCCACCTACTCTCCCACTTCTCCTGGCTGAGA3’
RX2 49+50 Rev.:
5’CCGGTCTCAGCCAGGAGAAGTGGGAGAGTAGGTGGAGCC3’
RX2 49+52 Fwd.:
5’CAAGGGCTCCACCTACAGCCTCACCAGCCCAGCCATCAGCCCAGATGAC
AGCGATGAGGAGAACTGAGA3’
RX2 49+52 Rev.:
5’CCGGTCTCAGTTCTCCTCATCGCTGTCATCTGGGCTGATGGCTGGGCTGG
TGAGGCTGTAGGTGGAGCC3’
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RX2 49+NS52 Fwd.:
5’CAAGGGCTCCACCCCCGACAACCCCGACTCCTCCACCGACACCTCCGAG
TCCACATACGAGCTGTGAG3’
RX2 49+NS52 Rev.:
5’CCGGCTCACCGCTCGTATGTGGACCCGGAGGTGTCGGTGGAGGAGTCGG
GGTTGTCGGGGGTGGAGC3’
RX2 49+52 S9A Fwd.:
5’CAAGGGCTCCACCTAGCAGCCTCACCAGCCCAGCCATCGCCCCAGATGA
CAGCAGTGAGGAGAACTGAGC3’
RX2 49+52 S9A Rev.:
5’CCGGGCTCAGTTCTCCTCATCGTCATCTGGGGCGATGGCTGGGCTGGTGA
GGCTGTAGGTGGAGCC3’
RX2 49+52 S13A Fwd.:
5’CAAGGGCTCCACCTACAGCCTCACCAGCCCAGCCATCAGCCCAGATGAC
GCCGATGAGGAGAAACTGAGC3’
RX2 49+52 S13A Rev.:
5’CCGGGCTCAGTTCTCCTCATCGGCGTCATCTGGGTCAGTGGCTGGGCTGG
TGACGCTGTAGGTGGAGCC3’
RX2 49+52 S9/13A Fwd.:
5’CAAGGGCTCCACCTACAGCCTCACCAGCCCAGCCATCGCCCCAGATGAC
GCCGATGAGGAGAACTGAGC3’
RX2 49+52 S9/13A Rev.:
5’CCGGGCTCAGTTCTCCT6CATCGGCGTCATCTGGGGCGATGGCTGGGCTG
GTGAGGCTGTAGGTGGAGCC3’
RX2 49M+52 Fwd.:
5’CAAGTACAGCCTCACCAGCCCAGCCATCAGCCCCAGATGACAGCGATGA
GGAGAACTGAGA3’
RX2 49M+52 Rev.:
5’CCGGTCTCAGTTCTCCTCATCGCTGTCATCTGGGCTGATGGCTGGGCTGG
TGAGGCTGTA3’
RX2 49+50 ATM Fwd.:
5’CAAGGGCTCCACCTACTCTCCCACTTCTCCTGGCGACCCAGCCCCAAACC
CACCACACTTCCCAACGAG3’
RX2 49+50 ATM Rev.:
5’CCGGCTCATGGGGAAGTGTGGTGGGTTTGGGGCTGGGTCGCCAGGAGAA
GTAGGAGAGTAGGTGGAGCC3’
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4.2.2 Existing plasmids used during this work
pUC19:
A small, high copy number E. coli plasmid containing portions of pBR322,
M13mp19 and a 54 bp MCS (Yanisch-Perron et al., 1985). GenBank Accession #:
X02514
pEGFP-C1 (CLONTECH):
An expression vector containing the modified (enhanced) cDNA sequence
encoding the green fluorescent protein from the jellyfish Aequoria victoria.
GenBank Accession #: U55763
MM126-10 (LS*MOCK):
A tetracycline-regulated expression vector (Tc-off), containing the resistance
genes for neomycin/G418 and ampicillin.  This vector contains the EBV origin
of replication, and is maintained episomally in EBNA1-positive cell lines
(Meininghaus et al., 2000).
MM172-2/1:
A vector based on MM126-10, that contains the genomic sequence for the N-
terminal part of the α-amanatin resistant, Pol II LS gene (A gift from Mark
Meininghaus, GSF, München).
MM128:
A vector based on MM126-10, that contains the genomic sequence of the C-
terminal part of the α-amanatin resistant, Pol II LS gene (A gift from Mark
Meininghaus, GSF, München).
4.2.3 Plasmids produced for this work
MM128-MCS:
A vector based on MM128, that is modified to include a multiple cloning site
(Age I, Pme I, Not I) before the STOP codon of the genomic sequence for the C-
terminal part of the α-amanatin resistant, Pol II LS gene.  The primer pairs wt>
& RDC17-2, and RDC17-3 & d31fl were used to amplify two fragments from
the plasmid MM128.  An overlap PCR protocol using the products from each of
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these reactions and primers wt‡  and d31, was used to produce a fusion
product of them both.  The primers 17-2 and 17-3 contain overlap sequences
(encoding the MCS) to enable this.  The overlap PCR product was digested with
the enzymes Ngo MIV, and Cla I, and ligated into the ??bp vector backbone of
MM128 following its digestion with the same enzymes.
pUC19-CTD:
A sub-cloning vector containing the coding sequence of the last exon of the α-
amanatin resistant, Pol II LS gene.  The primers wt‡ and d31 were used to
amplify a 1600 bp fragment from vector MM128-MCS, which was then ligated
blunt-ended, to pUC19 linearised with digestion with HincII.
RDC100wt (LS*wtMCS):
A tetracycline-regulated expression vector containing the full length, α-
amanatin resistant, Pol II LS gene, with a multiple cloning site inserted before
its STOP codon.  The ~ 14.5 kbp Sfi I - Apa LI digest product of the vector
MM128-MCS was ligated to the ~ 12 kbp Sfi I - Sex AI digest product of the
vector MM172-2/1.
RDC135wt (LS*wtEGFP):
A tetracycline-regulated expression vector containing the full length, α-
amanatin resistant, Pol II LS gene, with the coding sequence of EGFP inserted in
frame, before its STOP codon.  Primers EGFP Fwd., and EGFP Rev. were used to
amplify a 715 bp fragment from the plasmid pEGFP-C1.  The Not I – Age I -
digested PCR product was ligated to the ~ 26 kbp product of vector RDC100wt
following digestion with the same enzymes.
RX2 vectors (CTD49+:  50; 52, NS; 52 S9A; 52 S13A; 52 S9/13A; 50 ATM):
Vectors containing last exon mutants of the α-amanatin resistant, Pol II LS gene.
Mutation of the last CTD repeat was achieved by ligation of the 4274 bp pUC19-
CTD Sty I - Age I digestion product to synthesized, complementary
oligonucleotides incorporating the modified CTD sequences, and
corresponding overhangs for Sty I and Age I (see RX2 primers).  The primer
sequence was designed to destroy the Age I site following annealing.
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RX3 vectors (CTD49+:  50; 52, NS; 52 S9A; 52 S13A; 52 S9/13A; 50 ATM):
A vector based on MM128-MCS, that contains mutations in the genomic
sequence for the last CTD repeat, encoded within the C-terminal part of the
mouse, α-amanatin resistant, Pol II LS gene.  The ~ 10 kbp product of MM128-
MCS digestion with Ngo MIV and Cla I, was ligated to the ~1600 bp product of
RX2 digestion with Xmn I, Ngo MIV and Cla I.
RX4 vectors (CTD49+:  50; 52, NS; 52 S9A; 52 S13A; 52 S9/13A; 50 ATM):
A tetracycline-regulated expression vector containing last CTD repeat mutants
of the mouse, full-length, α-amanatin resistant, Pol II LS gene. The ~ 13 kbp
product of RX3 digestion with Nhe I, Not I and Eco105 I was ligated to the ~ 13
kbp product of RC100wt with Not I, Nhe I and Sex AI.
4.2.4 Bacteria
DH5α: E. coli strain purchased from Invitrogen GmbH, Karlsruhe.  Used for the
routine cloning of plasmid DNA smaller than 5 kbp.
DH10B:E. coli strain purchased from Invitrogen GmbH, Karlsruhe.  Used for the
cloning of plasmid DNA larger than 5 kbp
4.2.5 Probes for Northern-blot anaylsis
For the hsp70A-gene:
A 2.4 kb EcoRI-fragment from pUCHsp70A (Stressgene)
4.3 Eucaryotic cell lines
4.3.1 Basic cell lines
Raji:
A human, EBV-positive Burkitt’s lymphoma cell line (endemic Burkitt’s
lymphoma) containing a t(8;14) translocation (Pulvertaft, 1964).
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BL29:
A human, EBV-positive Burkitt’s lymphoma cell line
Elijah:
A human, EBV-positive Burkitt’s lymphoma cell line
Rosi:
A human lymphoblastic cell line
L187:
A human lymphoblastic cell line
4.3.2 Stably transfected cell lines
Cell line Name Plasmid Parent cell line Resistance
MM233-2 Raji1LS*mock MM126-10 Raji neo
XR4-100 RosiLS*mock              “ Rosi  “
MM233-4 Raji1LS*∆31 MM217b Raji  “
MM233-6 Raji1LS*∆5 MM203B2 Raji  “
RC100wt RajiLS*wtMCS RDC100wt Raji  “
XR4wtMCS RosiLS*wtMCS        “ Rosi  “
RC135wt RajiLS*wtEGFP RDC135wt Raji  “
XR4-101 RajiLS*49+50 RX4-50 Raji  “
XR4-201 RosiLS*49+50        “ Rosi  “
XR4-301 ElijahLS*49+50        “ Elijah  “
XR4-401 BL29LS*49+50        “ BL29  “
XR4-102 RajiLS*49+52 RX4-52 Raji  “
XR4-202 RosiLS*49+52        “ Rosi  “
XR4-302 ElijahLS*49+52        “ Elijah  “
XR4-402 BL29LS*49+52        “ BL29  “
XR4-103 RajiLS*49+NS52 RX4-NS Raji  “
XR4-203 RosiLS*49+NS52        “ Rosi  “
XR4-203 RosiLS*49+NS52        “ Elijah  “
XR4-203 RosiLS*49+NS52        “ BL29  “
XR4-104 RajiLS*49+S9A RX4-S9A Raji  “
XR4-204 RosiLS*49+S9A        “ Rosi  “
XR4-105 RajiLS*49+S13A RX4-S13A Raji  “
XR4-205 RosiLS*49+S13A        “ Rosi  “
XR4-106 RajiLS*49+S9/13A RX4-S9/13A Raji  “
XR4-206 RosiLS*49+S9/13A        “ Rosi  “
XR4-107 RajiLS*49+50ATM RX4-ATM Raji  “
XR4-207 RosiLS*49+50ATM        “ Rosi  “
XR4-108 RajiLS*49M+52 RX4-49M Raji  “
XR4-208 RosiLS*49M+52        “ Rosi  “
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5. Methods
The standard protein and molecular biology techniques used during this work
are described in detail in the following text: (Sambrook et al., 1989)
5.1 Bacterial cell culture
5.1.1 The maintenance and preparation of bacterial plasmids
Bacteria were cultured either on LB-agar plates in a bacterial incubator, or
in liquid LB medium in a thermoshuttler at 37 °C. overnight.  Liquid cultures
were produced through infection of 200-400 ml LB medium with a single
bacterial colony picked from an agar plate.  Transformed bacteria were selected
for the antibiotic resistance of the transformed plasmid through the addition of
antibiotic (kanamycin or Ampicillin) to growth media: liquid culture medium,
100 µg/ml; agar plates, 50µg/ml.
LB-medium: 20 mM MgSO4; 10 mM KCL; 1 % (w/v) Bacto-Tryptone; 0.5 % (w/v) Bacto-
yeast extract; 0.5 % (w/v) NaCl
LB-agar: 20 mM MgSO4; 10 mM KCl; 1 % (w/v) Bacto-Tryptone; 0.5 % (w/v) Bacto-
yeast extract; 0.5 % (w/v) NaCl; 1.2 % (w/v) Bacto-agar
5.1.2 Preparation of competent bacteria
To increase the efficiency of plasmid DNA uptake (transformation),
bacteria were treated with solutions of di-valent cations.  An LB plate was first
inoculated with a probe from a bacterial stock and grown overnight at 37 °C.  A
single colony was then used to inoculate 2.5 ml of LB medium, which was then
incubated overnight in a loose-capped vessel, with shaking.  The following day,
the entire overnight culture was used to inoculate 250 ml of LB medium
containing 20 mM MgSO4.  Bacteria were grown in a 1 dm
3 flask, with shaking,
at 37 °C until the absorbance at 600 nm (A 600) reached 0.4-0.6 (approx. 5-6 h).
Bacteria were pelleted at 4,5000 x g, 5 ’ at 4°C.  Medium was discarded and the
bacteria re-suspended in 0.4 volume (of the original culture volume) of ice-cold
TFB1.  Bacteria were incubated a further 5 ‘on ice before centrifugation (as
above), and re-suspension in 1/25 of the original culture volume of ice-cold
5.  Methods 83
TFB2 and incubated a further 15-60 ‘ on ice.  Aliquots of 200 µl bacteria were
snap-frozen in liquid nitrogen and removed to storage at –80 °C.
NOTE:  All vessels and pipettes must be pre-chilled:  for best results work in a
4°C lab.
TFB1: 30 mM Potassium acetate; 10 mM CaCl2; 50 mM MnCl2; 100 mM RbCl; 15 % glycerol.
Adjust to pH 5.8 with 1 M acetic acid; sterile filter (0.2 µm).
TFB2: 10 mM MOPS pH 6.5; 75 mM CaCl2; 10 mM RbCl; 15 % glycerol.  Adjust to pH 6.5
with 1 M KOH; sterile filter (0.2 µm).
5.1.3 Transformation of bacteria
For standard sub-cloning and production of large amounts of cloned
DNA, the recombination-deficient Escherichia Coli strain, DH10B was used.  For
transformation, 1 ng to 0.1 µg of plasmid DNA or 10 µl of ligation mixture was
added to 100 µl of competent cell suspension and incubated on ice for 30 ‘.
Cells were then subjected to heat shock at 42 oC for 30 ‘’ before returning to ice
for 2 ‘.  400 µl (4 volumes) of LB recovery medium was added to cells and
incubated at 37 oC for 1 h for cells to express resistance genes conferred by the
plasmid.  For routine transformations, 100 µl of suspension was plated onto LB-
agar plates containing ampicillin or kanamycin and grown at 37 oC for 16-18 h.
Following transformation of ligation mixtures, bacteria were pelleted by
pulsing in a microfuge at 10,000 x g before resuspending in 100 µl of LB media
and plating onto LB-agar plates.
5.1.3 Miniprep of plasmid DNA
Single colonies obtained from transformation of bacteria following ligation
reactions were used to inoculate 5 ml LB, and grown overnight.  Using the
alkaline lysis method (Birnboim, 1983), plasmid DNA was isolated from a
bacteria culture.  This method relies on the fact that high molecular weight
linear chromosomal DNA will be denatured when cells are lysed at pH 12.0-
12.6, whereas low molecular weight supercoiled plasmid DNA remains
unaffected.  Neutralisation of pH in the presence of high salt concentrations
subsequently precipitates chromosomal DNA, which can then be separated
from the mix.  The following protocol was routinely used:  5 ml of LB media
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containing appropriate antibiotic was inoculated with a single colony of
transformed bacteria in a 20 ml loose-capped tube.  The culture was incubated
overnight at 37 oC with vigorous shaking.  1.5ml of culture was then decanted
into a microfuge tube and centrifuged at maximum speed for 30 s in a
microfuge.  Medium was removed from the pellet by aspiration with a
disposable pipette tip, leaving the cell pellet as dry as possible.  The cell pellet
was re-suspended in 90 µl of alkaline lysis solution I by vigorous vortexing,
ensuring complete dispersal of bacterial cells. 180 µl of freshly prepared
alkaline lysis solution II was added, and mixed gently by inverting 5 times
before incubation at room temperature for 5 ‘.  To precipitate, 135µl of alkaline
lysis solution III was added, and then mixed by inverting, before centrifugation
at maximum speed for 5 ‘.  The resulting supernatant was transferred to a fresh
microfuge tube and mixed with 1 ml of ethanol to precipitate plasmid DNA,
and centrifuged at 10,000 x g for 5 ‘.  Supernatant was thoroughly removed
using a drawn out Pasteur pipette and pellets re-suspended in 100 µl of TE
buffer.  For screening of these crude preparations with restriction enzymes,
master mixes of enzymes and appropriate restriction enzyme buffers (Promega)
containing RNase A (pancreatic RNase, Sigma) were prepared, such that 10 µl
of mix could be added to 10µl of miniprep to give 0.5-3 units of enzyme
(depending on efficiency), 1x restriction enzyme buffer and 20 µg/ml RNase A.
Digests were incubated at appropriate temperatures for 2 h before separation
on agarose gels.
Solution I: 50 mM Tris-Cl; pH 8; 10 mM EDTA
Solution II: 0.2 M NaOH; 1 % SDS
Solution III: 3 M potassium acetate; 2 M glacial acetic acid
5.1.4 Maxi-prep of plasmid DNA
Large quantities of plasmids were purified using Qiagen Maxi-prep
protocols based on a modified alkaline lysis procedure.  Plasmid DNA is
recovered by running the bacterial lysate through an anion exchange column
under appropriate low-salt and pH conditions.  Following washing, the DNA
can be eluted by a high-salt buffer.
A single colony was picked from a freshly streaked selection plate and
used to inoculate a starter culture of 2-8 ml of selective LB medium and
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incubated for overnight at 37 oC on an orbital shaker.  The starter culture was
then diluted 1:500 into 100-300ml of selective LB medium and grown overnight
at 37 oC on an orbital shaker.  Cells were harvested by centrifugation at 6000 x g
for 15 ‘ at 4 oC.  Supernatant was discarded and pellets were re-suspended in 10
ml of chilled alkaline lysis solution I containing 100 µg/ml RNAase A.  10 ml of
alkaline lysis solution II was added to the suspension and mixed gently by
inverting.  Cells were lysed for 5 ‘ at room temperature before stopping the
reaction by addition of 10 ml alkaline lysis solution III and mixed again by
inverting.  Mixtures were incubated on ice for 20 ‘ to aid precipitation of cell
debris, genomic DNA and SDS.  The sample was then centrifuged at 20,000 x g
for 1 h, 4 oC.  The supernatant was then passed through a filter paper to remove
any residual precipitate and applied to a Qiagen column equilibrated with 10
ml of equilibration buffer and washed twice with 30 ml wash buffer.  The
bound plasmid was eluted in 15 ml elution buffer and precipitated by adding
10.5 ml (0.7 volumes) of room temperature isopropanol, followed by
centrifugation at 20,000 x g for 30 ‘ at 4 oC.  Pellets were re-suspended in 400 µl
TE and transferred to a microfuge tube.
Equilibration buffer: 50 mM MOPS, pH 7; 750 mM NaCl; 15 % ethanol
Wash buffer: 50 mM MOPS, pH 7; 1M NaCl; 15 % ethanol
Elution buffer: 50 mM Tris-Cl, pH 8.5; 1.25 M NaCl; 15 % ethanol
5.2 Eucaryotic cell culture
5.2.1 Cultivation of Burkitt’s lymphoma and lymphoblastoid cell lines
Both cell types grow in suspension culture at 37 °C in a 5 % CO2, water
saturated atmosphere.  Optimal growth is achieved at a density of 3 x 105
cells/ml, which may be approximately maintained by splitting cells 1:3 with
fresh medium every 3 days.
Cell culture medium: RPMI 1640-mediium; 10 % FCS; 2 mM L-glutamine; 100 U/ml
penicillin; 100 mg/ml streptomycin; 1 mM sodium pyruvate; 0.2 nM
Na2SeO3
For some experiments described, the medium was supplemented with:
α-Amanatin: Stock: 1 mg α-amanatin/ml in H2O.  Working concentration 2 µg/ml
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5.2.2 Assessment of cell number and viability
The number of living and dead cells in a given volume was calculated
using a Fuchs-Rosenthal haemocytometer.  100 µl of cell suspension was mixed
with an equal volume of 0.5 % (w/v in PBS) trypan blue solution.  In contrast to
the porous membrane of dead cells, the membrane integrity of living cells
prevents the entry of pigment, thereby allowing the number of clear (living)
and blue (dead) cells to be ascertained.  Percentage viability was calculated
using the formula:  100 x a/(a+b), where a= alive cell #, and b= dead cell #.
5.2.3 Storage of cell lines
Stocks of cell lines can be stored for several years in liquid nitrogen.  Cells
were split 1:1 with fresh medium one day before storage.  Cells were pelleted
(302 x g, 5 ‘), and medium discarded, before resuspension in storage medium (1
x 107 cells/ml) and transfer of 1 ml aliquots to 1.5 ml cryotubes.  Stocks were
first stored overnight at –80°C before transfer to storage facilities in liquid
nitrogen.
To revive stocks from storage, cryotubes were thawed at room
temperature for 3 ‘ before transfer to 30 ml RPMI 1640 medium.  Cells and
medium was mixed through inversion several times, before re-centrifugation
(302 x g, 5 ‘), and re-suspension in 10 ml fresh culture medium containing 20 %
FCS.  For an improved outcome with some cell lines, a slight tilt of the culture
flask allows living cells to collect together, thereby increasing cell-cell contact.
Storage medium: 10 % RPMI 1640; 10 % DMSO; 80 % FCS
5.2.4 Stable transfection of B-cells
For the production of stable cell lines, plasmid vectors were introduced
into cell lines, and a selection performed utilising an antibiotic resistance gene
expressed by the introduced vector.  For best results, cells should be split 1:1
one day prior to transfection.  2 x 107 cells are required per transfection.  Cells
were collected by centrifugation (302 x g, 5 ‘), and re-suspended at a density of 2
x 107 cells/ 250 µl in RPMI 1640 medium.  Cells were transferred to a 4 mm
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electroporation cuvette on ice, and mixed with 10 µg plasmid DNA.
Electroporation was performed using a voltage of 250 V and capacitance charge
of 960 µF.  Immediately following electroporation, 1 ml FCS was added to the
cuvette, before transfer of the cell/ FCS mixture to 9 ml fresh culture medium in
a flask.  Tetracycline (0.1 µg/ ml) must also be applied if the vectors transfected
contain the tetracycline-regulated, Tc-off system.  Two days following
transfection, the appropriate selection reagent for the vectors used was applied
to the cell culture medium.  Selection typically requires 2 weeks to recover a
viability of 95 %.  This technique produces a polyclonal cell line.  Monoclonal
cell lines can be produced by isolation, and cultivation of single cells if desired.
Neomycin (G418): Stock: 100 mg/ml in PBS; Working concentration 1 mg/ml
Tetracycline: Stock: 100 µg/ml in H2O (5 mg Tc must be dissolved first in 0.5 ml
EtOH before addition of 50 ml H20); Working concentration 0.1 µg/
ml
5.2.5 Induction of Tc-regulated expression
Expression of a Tc-regulated gene is controlled by the presence or absence
of Tc.  The vectors used in this work contain the Tc-off system:  gene expression
is silenced in the presence of Tc.  To induce gene expression, Tc was washed out
of the cells by repeated centrifugation and re-suspension in wash medium (3 x
in 50 ml/ 2 x 107 cells).  Cells were then transferred to 10 ml of culture medium
(without selection) for further growth.  Expression may be detected 4h
following induction, but optimally at +18 h.
Wash medium:  PBS; 1 % FCS
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5.3 Molecular biology techniques
5.3.1 Digestion of DNA using restriction endonucleases
Restriction enzymes were used as described by the manufacturer.  For the
analysis of plasmid ‘mini-prep’ DNA, multiple digests were performed in a
compatible buffer. For cloning purposes, DNA was precipitated between
individual digests to control, and reduce the detrimental effects of over
digestion.
5.3.2 Dephosphorylation of 5’ ends
To prevent the re-ligation of linearised vector containing compatible ends,
5’ dephosphorylation was performed.  Following digestion, DNA fragments
were incubated with 1 U calf intestinal alkaline phosphatase (CIP) for 1 h at
37°C., before separation on an agarose gel.
5.3.3 Filling in of DNA overhangs
To enable the ligation of non-compatible ends, overhanging (sticky) ends
may be filled in to produce universally-compatible (blunt) ends.  Linearised
DNA was treated with Klenow DNA polymerase for 1 h at 37 °C, in 1 x Klenow
buffer, as recommended by the manufacturer.  The reaction was stopped via
phenolisation or separation on an agarose gel.
5.3.4 Ligation of DNA fragments
Eqimolar amounts of DNA fragments (ca. 200 ng) were mixed together,
and heated to 45 °C for 5 ‘, before transfer to ice. Ligase buffer and T4 DNA
ligase were added, as recommended by the manufacturer, and incubated
overnight at 16 °C.  The entire ligation mixture was used for transformation.
5.3.5 Hybridisation of complementary oligonucleotides
For the production of linker DNA, 5’ phosphorylated complementary
oligonucleotides were hybridised together.  Equimolar amounts of
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oligonucleotide were mixed together and heated to 95 °C in a thermomixer for
10 ‘, and then allowed to slowly cool to RT.
5.3.6 Polymerase chain reaction
The standard polymerase chain reaction (PCR) was performed essentially
as recommended by the manufacturer.  For standard (analytical) applications,
Taq polymerase was used, whereas the proof-reading DNA polymerase, Pfu,
was used for cloning purposes.  In brief, 20 ng of the DNA template to be
amplified was mixed with 50 pmol of forward and reverse primers, 0.5 mM
dNTPs (dATP, dGTP, dCTP, dTTP), and 2.5 U Taq DNA polymerase, in a
volume of 50 µl 1 x polymerase buffer.  PCR was performed in a thermocycler.
Samples were first denatured at 95 °C for 5 ‘ before commencement of the
amplification stage, and for 30 ‘’ between each cycle thereafter.  The annealing
temperature used was 2 °C lower than the calculated melting temperature for
the primers used.  The elongation temperature, and elongation time used was
dependent on the DNA polymerase used.   Taq polymerase has an optimal
elongation rate of 1.5 kbp/min at 72 °C; Pfu polymerase has an optimal
elongation rate of 500 bp/min at 73 °C.   Following the final cycle, a further
elongation step of 5 ‘ was performed to ensure complete synthesis.
5.3.7 Isolation of DNA for cloning and analysis
The DNA products of PCR and restriction enzyme digests were isolated,
essentially as described (sambrook, maniatis).  Purification of DNA from non-
DNA contaminants was achieved through phenolisation, followed by ethanol
precipitation.  Purification, or analysis of a mixture of different-sized DNA was
achieved via separation over a 1 x TAE 0.7 % agarose gel, containing ethidium
bromide (0.5 µg/ ml).  For the purification of DNA, a low-melting type of
agarose was used.  A band of interest was removed from the gel and melted at
68 °C in a 1.5 ml reagent tube.  An equal volume of phenol (pH 8) was then
mixed with the melted gel, before centrifugation at 15000 x g to remove
unwanted proteins.  The resulting supernatant was repeatedly phenolised (2-3
x) before precipitation, and re-suspension in a suitable volume of TE pH 8.0.
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5.4 Methods for the analysis of DNA and RNA
5.4.1 Radioactive labelling of DNA fragments
The multi-prime method (Feinberg and Vogelstein, 1983; Feinberg and
Vogelstein, 1984) was used for the labelling of DNA fragments.  2.5-25 ng DNA
was labelled using the rediprime kit (Amersham Pharmacia, Freiburg) and 50 µCi
[α-32P]-dCTP (3000 Ci/ mmol, 10 mCi/ ml), as recommended by the
manufacturer.  Labelled probe was separated from non-incorporated nucleotide
label using a G50 sephadex column.  The incorporation of label was measured
using a bench top radioisotope counter.  Labelled probes were denatured by
heating to 95 °C, for 5 ‘, before use.
5.4.2 Isolation of total RNA
Large amounts of total RNA were extracted from cells using a
guanidinium thiocyanate-phenol-chloroform based reagent (TriFast: Peqlab,
Erlangen).  0.5-1 x 107 cells were harvested by centrifugation (302 x g) and re-
suspended in 1 ml of Trifast reagent.  RNA was extracted and precipitated, as
recommended by the manufacturer, before re-suspension in a 50 µl of DEPC-
treated water.  To increase solubility, samples were frozen at –80 °for >30 ‘ to
improve pellet disruption, before mixing at 55 °C using a thermomixer.  To
measure RNA concentration, 1 µl of sample was diluted in 199 µl Tris-Cl pH 7.5
and the absorbance at 260 nm measured using a spectrophotometer.
5.4.3 Northern-blot analysis
10 µg of total RNA was mixed with 20 µl of RNA loading buffer and
denatured at 65 °C for 5 ‘.  RNA was separated on a 1 % formaldehyde-agarose
gel in 1 x MOPS buffer overnight with a voltage of 0.7 V/ cm.  Following
separation, a UV (254 nm) trans-illuminator was used to visualise the RNA
loading of the gels, and photographed.  RNA was transferred to a nylon
membrane (Hybond N+) using 10x SSC solution.  Baking of the membrane at
80°C for 1 h covalently linked the RNA to the membrane.  RNA transfer can be
visualised by UV illumination.
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Before hybridisation of probe to the membrane, pre-hybridisation steps
are required to reduce background.  The membrane must first be washed at 65
°C in 1 % SDS/ 0.1 x SSC for 1 h, followed by a further 1 h at 65 °C in Church
hybridisation buffer.  Hybridisation was performed at 65 °C overnight in 5 ml
fresh Church hybridisation buffer containing 1 x 107 DPM of the radioactive
probe (5.4.1).  Membranes were then washed 3 times in 10 ml of a solution of 1
% SDS/ 0.1 x SSC, at a temperature of between 40-65 °C, depending on the
probe used.  Membranes were then dried, and exposed to X-ray film overnight.
If a gene is expressed at low-levels, the use of an enhancer screen may be
required, in which case exposure must be performed at –80 °C.
20 x SSC: 3 M NaCl; 300 mM Tri-sodium citrate/ NaOH pH 7.0
Church hybridisation buffer: 400 mM Na2HPO4; 200 mM NaH2PO4; pH 7.1; 7 % (w/v) SDS;
1 mM EDTA/ NaOH pH 8.0
10 x MOPS: 0.4 M MOPS (free-acid); 100 mM Na-acetate; 10 mM
EDTA/NaOH pH 8.0; pH 7.0 (adjusted with 10 N NaOH)
RNA loading buffer; 50 % (v/v) formamide; 2.2 M formaldehyde; 1 x MOPS buffer;
50 µg/ml ethidium bromide; 0.2 % (w/v) bromophenol blue
1 % Formaldehyde-agarose gel: 2.2 M formaldehyde; 1 x MOPS buffer; 1 % (w/v) agarose
5.4.4 Preparation of cell nuclei
The preparation of nuclei for nuclear run-on reactions was performed
essentially as described (Eick and Bornkamm, 1986; Greenberg and Ziff, 1984).
1 x 108 cells from an exponentially growing culture were pelleted by
centrifugation (302 x g, 4 °C), before washing in 40 ml ice-cold PBS, re-
centrifugation, and re-suspension in 10 ml ice-cold lysis buffer.  Following 15 ‘
incubation on ice, nuclei were pelleted by centrifugation (472 x g), before careful
re-suspension in 1 ml storage buffer (2 x 107 nuclei/ 100 µl).  Nuclei were
dispensed in 100 µl aliquots, which were then snap-frozen in liquid nitrogen,
before storage at –80°C.
Lysis buffer: 10 mM Tris/HCl pH 7.5; 10 mM MgCl2; 10 mM NaCl; 0.5 % (w/v) NP40
Storage buffer: 50 mM Tris/HCl pH 8.3; 5 mM MgCl2; 0.1 mM EDTA/NaOH pH 8.0; 40 %
(v/v) glycerol
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5.4.5 Nuclear run-on
Nuclear run-on reactions were performed essentially as described (Eick
and Bornkamm, 1986; Greenberg and Ziff, 1984).  100 µl (2 x 107 nuclei) of cell
nuclei preparation (5.4.4) was thawed gently on ice.  At this point, 4 µl 0.1 mg/
ml α-amanatin may be applied to the nuclei, followed by a further 10 ‘
incubation (optional).  The run-on reaction is commenced with the addition of
100 µl of 2 x run-on buffer (with or without sarkosyl), containing 100 µCi [α-
32P]-CTP (800 Ci/ mmol, 10 mCi/ ml) to the nuclei.  Reactions were incubated
at 28 °C for 15 ‘, after which 50 U DNase 1 (RNase-free) was applied and the
mixture incubated for a further 12 ‘ at RT.  The DNase I treatment was repeated
if sarkosyl was included in the run-on buffer.  The nuclei were then lysed with
20 µl proteinase K/ SDS, and incubated for at least 1 hour at 37 °C.  The nuclear
transcripts were then separated from non-incorporated ribonucleotides using a
sephadex G50 column, and collected in a 500 µl volume of TE buffer.  The
incorporation of label was measured using a bench top radioisotope counter,
before denaturing for 5 ‘ at 65 °C and hybridisation to a CLONTECH Atlas
cDNA membrane.
4 x run-on buffer: 600 mM KCl; 10 mM MgCl2; 1 mM each NTP; 20 mM Tris/HCl pH
8.0; 2.4 % (w/v) sarkosyl (optional)
Proteinase K/ SDS: 2.5 mg/ ml proteinase K; 2.5 % (w/v) SDS
5.4.6 Preparation and washing of Atlas cDNA membranes
The Atlas cDNA membranes were prepared as directed by the
manufacturer.  In brief, membranes were activated before use by boiling in 0.5
% SDS/ TE pH 8.0 for 10 minutes prior to pre-hybridisation.  Membranes were
pre-hybridised with 1.5 mg sheared salmon-sperm DNA/ membrane, in 15 ml
Church hybridisation buffer (5.4.3) at 65 °C for > 1 h (or overnight).
Hybridisation was performed in 5 ml Church hybridisation buffer containing
the radioactively labelled probe, and incubated with rotation for 48 h at 65°C.
Membranes were washed at 65 °C using wash buffers of different
stringencies as follows:  2 x with wash buffer I; 2 x with wash buffer II; 1 x
RNase digestion in wash buffer III, 15 ‘ at RT; 1 x in wash buffer II.  Membranes
were packed wet, in plastic film and exposed to sensitive X-ray film
(BioMaxMS, Eastman Kodak, New York, USA) at –80 °C.
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Wash buffer I: 0.1 x SSC; 1 % (w/v) SDS
Wash buffer II: 0.1 x SSC; 0.5 % SDS
Wash buffer  III: 2 x SSC; 1 mM EDTA/NaOH pH 8.0; 2 µg/ ml RNase A
5.5 Methods for the analysis of protein
5.5.1 Preparation of protein extracts
For the analysis of total cellular protein, SDS-PAGE loading buffer was
used.  3 x 105 cells were pelleted by centrifugation (302 x g, 5 ‘) in a 1.5 ml
reaction vessel.  Cells were then re-suspended in 100 µl of SDS loading buffer.
The viscous lysate was repeatedly drawn through a narrow pipette tip to shear
genomic DNA, before denaturing by boiling at 95 °C for 5 ‘.  After briefly
cooling on ice, samples were centrifuged (15000 x g, 10 ‘) to clear insoluble
contaminants.  10 µl (30,000 cells) of lysate was loaded per lane on an SDS-
PAGE gel.
SDS-PAGE loading buffer: 200 mM Tris/HCl pH 6.8; 8 % (w/v) SDS; 40 % glycerol; 400
mM DTT; 0.2 mM EDTA/NaOH pH8.0; 0.2% (w/v)
bromophenol blue
5.5.2 Immunoprecipitation
Treatment of cells with buffers of different stringencies allows the
extraction of different cellular compartments.
Membrane and cytosolic fraction
2 x 107 cells were harvested by centrifugation (302 x g, 5 ‘), washed once in
20 ml PBS, re-centrifuged and re-suspended in 500 µl ice-cold NP40 lysis buffer.
Cells were mixed gently and incubated 5 ‘ on ice before pelleting of the nuclei
(472 x g, 5 ‘, 4 °C).  The supernatant was carefully removed for
immunoprecipitation, or storage at –80 °C.  The remaining nuclei can be used
for extraction of nuclear proteins.
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Total (soluble and non-soluble) nuclear fraction
Nuclei produced by the previous method may be digested to release their
non-soluble protein content (for example, chromatin-bound factors).  Nuclei
were re-suspended in 100 µl of Dahmus digest buffer (Baskaran et al., 1993) and
incubated on ice for 30 ‘, before the addition of 500 µl RIPA extraction buffer.
Nuclei were incubated on ice for 10 ‘ before clearing by centrifugation (15000 x
g, 5 ‘, 4 °C).  The supernatant was carefully removed for immunoprecipitation,
or storage at –80 °C.
Soluble nuclear fraction
Nuclei produced by the previous method may be ‘bled’ to release their
soluble protein content.  Nuclei were re-suspended in 500 µl of a variation of
high-stringency RIPA buffer and incubated on ice for 10 ‘, before clearing by
centrifugation (15000 x g, 5 ‘, 4 °C).  The supernatant was carefully removed for
immunoprecipitation, or storage at –80 °C.
NP40 lysis buffer*: 10 mM NaCl; 10 mM MgCl2; 10 mM Tris pH 7.5; 5 mM EDTA; 0.5 %
NP40
Dahmus digest buffer*: 25 mM Tris/HCl pH 8.0; 2.5 mM Mg-acetate; 2 mM CaCl2; 50 µM
EDTA; 0.1 mM DTT; 12.5 % glycerol; 100 µg/ml each of DNase and
RNase
RIPA buffer*: 50 mM Tris/HCl pH 7.0; 300 mM NaCl; 1 % Triton X100; 1 % Na-
deoxycholate
* Buffers were supplemented with: 1 mM PMSF; complete protease inhibitor cocktail (Roche
Diagnostics, Mannheim); 1 mM Na-orthovanadate; 1 mM Na-molybdate; 10 mM NaF
Immunoprecipitation (IP) of HA-tagged proteins was performed using
anti-HA (3F10) affinity matrix beads, as recommended by the manufacturer
(Roche Diagnostics, Mannheim).  In brief, beads were washed 3 x in RIPA buffer (50 µl
slurry/ IP), before re-suspension in fresh RIPA buffer  (50 µl/ IP) and
dispensing to lysates.  Lysate/ bead mixtures were incubated on ice for 30 ‘,
with gentle mixing by inversion (never vortex!) every 5 ‘.  Lysate/ bead
mixtures were then inversion-mixed at 4 °C for 4 hours.  Beads were collected
by centrifugation, washed extensively with IP buffer, and the solubilised in SDS
loading buffer at 95 °C for 10 ‘ before SDS PAGE analysis.
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5.5.3 SDS-polyacrylamide gel electrophoresis
Denaturing  (SDS) polyacrylamide gel electrophoresis (PAGE) was
performed essentially as described (Laemmli, 1970).  30,000 cells, or 10 µg
protein solubilised in SDS-PAGE loading buffer were denatured by boiling at
95°C before separation on an SDS-PAGE gel.  Stained marker standards were
run simultaneously on the same gel for the estimation of molecular weight.  The
acrylamide content of SDS-PAGE gels was varied according to the size of
protein being examined (described in detail (Sambrook et al., 1989)) in
conjunction with a 5 % acrylamide stacking gel.  Gels with a thickness of 0.75
mm were separated using a constant current of 30 mA/ gel in 1 x SDS running
buffer, with cooling.  Following separation, gels were used for Western blotting
(5.5.4).
10 x SDS-PAGE running buffer: 0.25 M Tris-base; 2.5 M glycine; 0.5 % (v/v) SDS
5.5.4 Western-blotting and immuno-detection of proteins
The western-blotting technique involves the immobilisation of proteins
resolved by SDS-PAGE, and their detection using specific antibodies.
Proteins separated on SDS-PAGE gels were transferred to a PVDF
membrane using a wet transfer system with all components soaked beforehand
in transfer buffer.  The gel was placed on top of a piece of Whatman 3MM filter
paper and sponge and overlaid with PVDF membrane, pre-washed in Methanol
and equilibrated in transfer buffer.  The blotting sandwich was completed by
the addition of a second layer of filter paper and sponge.  Transfer in a cassette
assembly was carried out at 150 mA for 90 ‘.
Following transfer, PVDF membranes were washed repeatedly in 1 x
TBS/ Tween-20 to remove any gel remnants from the transfer procedure.  The
remaining protein-binding capacity of the gel was neutralised by incubation in
blocking buffer >1 h, with shaking.  Excess blocking reagent was removed by
washing 3 x using the appropriate wash buffer, before incubation of the
membrane with primary antibody diluted to its correct working concentration
in 5 % BSA/ washing buffer, 1 h, at RT.  Membranes were washed 3 x with
wash buffer to remove excess primary antibody.  A peroxidase-conjugated,
secondary antibody, specific for the isotype of the primary antibody used, was
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applied to the membrane at its correct working concentration, diluted in 5 %
BSA/ washing buffer, for 1 h, at RT.  Excess antibody was removed by washing
3 x in wash buffer.
Protein-antibody complexes were detected on X-ray film using a
chemoluminesence reaction catalysed by the antibody-conjugated peroxidase.
The ECL solution was used as substrate for this reaction, following the
manufacturer’s protocol.
Transfer buffer: 1 x SDS-PAGE running buffer; 10 % (v/v) methanol
Blocking buffer: 5 % (w/v) fat-free milk powder; wash buffer
Wash buffer I: 1 x PBS; 0.05 % Tween-20
Wash buffer II: 1 x TBS; 0.05 % Tween-20
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